{"DataElement":{"publicId":"4723846","version":"1","preferredName":"NCI CTEP Simplified Disease Classification Terminology MedDRA Version 10 Code","preferredDefinition":"The coded response indicating the MedDRA code Version 10 used in the NCI Simplified Disease Classification (SDC) Terminology for diagnoses.","longName":"CTEP_SDC_MED_V10_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4723845","version":"1","preferredName":"NCI CTEP Simplified Disease Classification Terminology Disease Code","preferredDefinition":"The NCI Cancer Therapy Evaluation Program (CTEP) Simplified Disease Classification (SDC), a three level hierarchy of Category, Sub-Category, and coding Term intended to provide an intuitive classification of neoplastic diseases to meet the needs of CTEP while still allowing reporting based on the Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.  All CTEP SDC Terms are matched to NCIt concepts, which are linked to SDC Categories and Sub-Categories through Concept_In_Subset association relationships._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system of numbered categories for representation of data.","longName":"4723843v1.0:2607556v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"4723843","version":"1","preferredName":"NCI CTEP Simplified Disease Classification Terminology","preferredDefinition":"The NCI Cancer Therapy Evaluation Program (CTEP) Simplified Disease Classification (SDC), a three level hierarchy of Category, Sub-Category, and coding Term intended to provide an intuitive classification of neoplastic diseases to meet the needs of CTEP while still allowing reporting based on the Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.  All CTEP SDC Terms are matched to NCIt concepts, which are linked to SDC Categories and Sub-Categories through Concept_In_Subset association relationships.","longName":"C102905","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCI CTEP Simplified Disease Classification Terminology","conceptCode":"C102905","definition":"The NCI Cancer Therapy Evaluation Program (CTEP) Simplified Disease Classification (SDC), a three level hierarchy of Category, Sub-Category, and coding Term intended to provide an intuitive classification of neoplastic diseases to meet the needs of CTEP while still allowing reporting based on the Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.  All CTEP SDC Terms are matched to NCIt concepts, which are linked to SDC Categories and Sub-Categories through Concept_In_Subset association relationships.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDBCC65-13C9-B6F0-E050-BB89AD436073","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"ONEDATA","dateModified":"2015-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2607556","version":"1","preferredName":"Diseases and Disorders Code","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function. (from Wikipedia):A system, often of numbered categories, for representation of data.","longName":"C2991:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AF1FF70-1439-6EC1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-05","endDate":null,"createdBy":"UMLLOADER_CTOM","dateCreated":"2007-03-05","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDBCC65-13D7-B6F0-E050-BB89AD436073","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4722338","version":"1","preferredName":"MedDRA Version 10 Code","preferredDefinition":"An international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The MedDRA Maintenance and Support Services Organization holds a contract with the International Federation of Pharmaceutical Manufacturers Associations to maintain and support the implementation of the terminology._A system of numbered categories for representation of data.","longName":"4722338v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"NUMBER","minLength":null,"maxLength":"12","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"10024534","valueDescription":"Lip and Oral Cavity Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3794704","version":"1","preferredName":"Lip and Oral Cavity Squamous Cell Carcinoma","longName":"3794704","preferredDefinition":"A squamous cell carcinoma arising from the lip or the oral cavity.  The oral cavity squamous cell carcinoma usually arises from the buccal mucosa, tongue, or gums.  It occurs predominantly in adults who use tobacco and alcohol and has a tendency to metastasize early to lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lip and Oral Cavity Squamous Cell Carcinoma","conceptCode":"C42690","definition":"A squamous cell carcinoma arising from the lip or the oral cavity.  The oral cavity squamous cell carcinoma usually arises from the buccal mucosa, tongue, or gums.  It occurs predominantly in adults who use tobacco and alcohol and has a tendency to metastasize early to lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E010110A-EA5C-64DE-E040-BB89AD431324","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-23D6-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10023843","valueDescription":"Laryngeal Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3794706","version":"1","preferredName":"Laryngeal Squamous Cell Carcinoma","longName":"3794706","preferredDefinition":"A squamous cell carcinoma arising from the larynx.  It is the most common type of laryngeal carcinoma.  The site of origin within the larynx influences the symptoms, histologic characteristics, and clinical behavior of squamous cell carcinoma.  The laryngeal squamous cell carcinomas can be glottic, supraglottic, and transglottic.  Glottic carcinoma is the most frequent form of laryngeal carcinoma in the United States.  Microscopically, squamous cell carcinomas of the larynx are similar in their appearance to squamous cell carcinomas arising elsewhere (adapted from Sternberg's Diagnostic Surgical Pathology, 3rd ed., 1999).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laryngeal Squamous Cell Carcinoma","conceptCode":"C4044","definition":"A squamous cell carcinoma that arises from the larynx.  It is the most common histologic type of laryngeal carcinoma.  It can arise from the glottis, supraglottic area, or it can be transglottic.  Glottic squamous cell carcinoma is the most frequent laryngeal carcinoma in the United States.  The symptoms, clinical behavior and the prognosis depend on the site of origin within the larynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E010110A-EA82-64DE-E040-BB89AD431324","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-23EB-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10060121","valueDescription":"Head and Neck Squamous Cell Carcinoma","ValueMeaning":{"publicId":"4722786","version":"1","preferredName":"Head and Neck Squamous Cell Carcinoma","longName":"4722786","preferredDefinition":"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Squamous Cell Carcinoma","conceptCode":"C34447","definition":"A squamous cell carcinoma that arises from any of the following anatomic sites: lip and oral cavity, nasal cavity, paranasal sinuses, pharynx, larynx, and salivary glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-23F6-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-240E-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600168","valueDescription":"Head and Neck Precancerous Condition","ValueMeaning":{"publicId":"4722788","version":"1","preferredName":"Head and Neck Precancerous Condition","longName":"4722788","preferredDefinition":"A premalignant pathologic process that affects the anatomic structures of the head and neck.  Representative examples include oral leukoplakia and leukoplakia of the vocal cords.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Head and Neck Precancerous Condition","conceptCode":"C27642","definition":"A premalignant pathologic process that affects the anatomic structures of the head and neck.  Representative examples include oral leukoplakia and leukoplakia of the vocal cords.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-241C-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2435-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025960","valueDescription":"Malignant Head and Neck Neoplasm","ValueMeaning":{"publicId":"4722789","version":"1","preferredName":"Malignant Head and Neck Neoplasm","longName":"4722789","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Head and Neck Neoplasm","conceptCode":"C4013","definition":"A primary or metastatic malignant neoplasm affecting the head and neck.  Representative examples include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-2441-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-245A-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10043353","valueDescription":"Testicular Seminoma","ValueMeaning":{"publicId":"3895710","version":"1","preferredName":"Testicular Seminoma","longName":"3895710","preferredDefinition":"A malignant germ cell tumor arising from the testis.  It is believed that it is derived from the sexually undifferentiated embryonic gonad.  Treatment with radiotherapy is highly successful when the tumor is diagnosed in localized stages, which represents the majority of presentations of seminoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Testicular Seminoma","conceptCode":"C7328","definition":"A malignant germ cell tumor arising from the testis.  It is believed that it is derived from the sexually undifferentiated embryonic gonad.  Treatment with radiotherapy is highly successful when the tumor is diagnosed in localized stages, which represents the majority of presentations of seminoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6374574-94AC-5E51-E040-BB89AD431AE9","latestVersionIndicator":"Yes","beginDate":"2013-09-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-09-12","modifiedBy":"ONEDATA","dateModified":"2013-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-246E-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10043321","valueDescription":"Malignant Testicular Non-Seminomatous Germ Cell Tumor","ValueMeaning":{"publicId":"4722791","version":"1","preferredName":"Malignant Testicular Non-Seminomatous Germ Cell Tumor","longName":"4722791","preferredDefinition":"A classification of testicular cancers that arise in specialized sex cells called germ cells. Nonseminomas include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Non-Seminomatous Germ Cell Tumor","conceptCode":"C5027","definition":"A classification of testicular cancers that arise in specialized sex cells called germ cells. Nonseminomas include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-247B-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2494-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10052311","valueDescription":"Ovarian Nondysgerminomatous Germ Cell Tumor","ValueMeaning":{"publicId":"4722793","version":"1","preferredName":"Ovarian Nondysgerminomatous Germ Cell Tumor","longName":"4722793","preferredDefinition":"A malignant germ cell tumor other than dysgerminoma that arises from the ovary.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Non-Dysgerminomatous Germ Cell Tumor","conceptCode":"C102870","definition":"A malignant germ cell tumor other than dysgerminoma that arises from the ovary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-24A1-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-24BA-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10052759","valueDescription":"Ovarian Dysgerminoma","ValueMeaning":{"publicId":"4722795","version":"1","preferredName":"Ovarian Dysgerminoma","longName":"4722795","preferredDefinition":"A malignant germ cell tumor arising from the ovary.  Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei.  The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumor stage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Dysgerminoma","conceptCode":"C8106","definition":"A malignant germ cell tumor arising from the ovary.  Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei.  The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumor stage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-24C7-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-24E0-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10018204","valueDescription":"Malignant Germ Cell Tumor","ValueMeaning":{"publicId":"4722797","version":"1","preferredName":"Malignant Germ Cell Tumor","longName":"4722797","preferredDefinition":"A gonadal or extragonadal malignant neoplasm that arises from germ cells. Representative examples include embryonal carcinoma, yolk sac tumor, and seminoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Germ Cell Tumor","conceptCode":"C4925","definition":"A gonadal or extragonadal malignant neoplasm that arises from germ cells. Representative examples include embryonal carcinoma, yolk sac tumor, and seminoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-24ED-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2506-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10015790","valueDescription":"Extragonadal Germ Cell Tumor","ValueMeaning":{"publicId":"3322765","version":"1","preferredName":"Extragonadal Germ Cell Tumor","longName":"3322765","preferredDefinition":"A germ cell tumor arising in an anatomic site other than the testis or ovary (e.g., central nervous system, lung, mediastinum, and retroperitoneum).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extragonadal Germ Cell Tumor","conceptCode":"C3918","definition":"A germ cell tumor arising in an anatomic site other than the testis or ovary (e.g., central nervous system, lung, mediastinum, and retroperitoneum).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3714D57-A897-7A8F-E040-BB89AD43536C","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-251A-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10054184","valueDescription":"Small Intestinal Carcinoma","ValueMeaning":{"publicId":"3210728","version":"1","preferredName":"Small Intestinal Carcinoma","longName":"3210728","preferredDefinition":"A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Intestinal Carcinoma","conceptCode":"C7724","definition":"A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9552-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-252F-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10041115","valueDescription":"Small Intestinal Adenocarcinoma","ValueMeaning":{"publicId":"4722799","version":"1","preferredName":"Small Intestinal Adenocarcinoma","longName":"4722799","preferredDefinition":"An adenocarcinoma that arises from the small intestine.  Histologic variants include mucinous adenocarcinoma and signet ring cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Intestinal Adenocarcinoma","conceptCode":"C7888","definition":"An adenocarcinoma that arises from the small intestine.  Histologic variants include mucinous adenocarcinoma and signet ring cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-253D-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2556-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065859","valueDescription":"Infantile Fibrosarcoma","ValueMeaning":{"publicId":"3179353","version":"1","preferredName":"Infantile Fibrosarcoma","longName":"3179353","preferredDefinition":"A fibrosarcoma, occurring in infants and young children, sharing identical morphologic features with adult fibrosarcoma.  The prognosis is generally much more favorable than for adult fibrosarcoma, and it rarely metastasizes.  It usually affects the superficial and deep soft tissues of the extremities.  The majority of infantile fibrosarcomas carry the t(12;15)(p13;q26) translocation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infantile Fibrosarcoma","conceptCode":"C4244","definition":"A fibrosarcoma that occurs in infants.  It shares identical morphologic features with adult fibrosarcoma but carries the t(12;15)(p13;q25) translocation that results in ETV6-NTRK3 gene fusion.  It usually affects the superficial and deep soft tissues of the extremities.  The prognosis is generally much more favorable than for adult fibrosarcoma, and it rarely metastasizes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-84D4-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B4FE-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10024193","valueDescription":"Leiomyosarcoma","ValueMeaning":{"publicId":"2562491","version":"1","preferredName":"Leiomyosarcoma","longName":"2562491","preferredDefinition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women. It is characterized by a proliferation of neoplastic spindle cells. Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leiomyosarcoma","conceptCode":"C3158","definition":"An uncommon, aggressive malignant smooth muscle neoplasm, usually occurring in post-menopausal women.  It is characterized by a proliferation of neoplastic spindle cells.  Morphologic variants include epithelioid, granular cell, inflammatory and myxoid leimyosarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C128-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-09-27","endDate":null,"createdBy":"PWEST","dateCreated":"2002-09-27","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B512-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10039494","valueDescription":"Soft Tissue Sarcoma","ValueMeaning":{"publicId":"3384698","version":"1","preferredName":"Soft Tissue Sarcoma","longName":"3384698","preferredDefinition":"A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Sarcoma","conceptCode":"C9306","definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9A3DDB0-75C8-1600-E040-BB89AD432CFF","latestVersionIndicator":"Yes","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B526-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10042866","valueDescription":"Synovial sarcoma","ValueMeaning":{"publicId":"2568843","version":"1","preferredName":"Synovial sarcoma","longName":"2568843","preferredDefinition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Synovial Sarcoma","conceptCode":"C3400","definition":"A malignant neoplasm characterized by the chromosomal translocation t(X;18)(p11;q11).  It can occur at any age, but mainly affects young adults, more commonly males.  Although any site can be affected, the vast majority of the cases arise in the deep soft tissues of extremities, especially around the knee.  Microscopically, synovial sarcoma is classified as monophasic (with a spindle or epithelial cell component) or biphasic (with both spindle and epithelial cell components).  Synovial sarcomas can recur or metastasize to the lungs, bones, and lymph nodes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9F8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B53A-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065867","valueDescription":"Alveolar Rhabdomyosarcoma","ValueMeaning":{"publicId":"3179233","version":"1","preferredName":"Alveolar Rhabdomyosarcoma","longName":"3179233","preferredDefinition":"A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alveolar Rhabdomyosarcoma","conceptCode":"C3749","definition":"A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CD32-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"ONEDATA","dateModified":"2010-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B54E-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065868","valueDescription":"Embryonal Rhabdomyosarcoma","ValueMeaning":{"publicId":"3179343","version":"1","preferredName":"Embryonal Rhabdomyosarcoma","longName":"3179343","preferredDefinition":"A poorly circumscribed morphologic variant of rhabdomyosarcoma.  It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.  There are three histologic types, spindle cell, botryoid and anaplastic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonal Rhabdomyosarcoma","conceptCode":"C8971","definition":"A poorly circumscribed morphologic variant of rhabdomyosarcoma.  It is characterized by the presence of primitive skeletal muscle differentiation in any stage of myogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-8366-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B562-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10053571","valueDescription":"Melanoma","ValueMeaning":{"publicId":"2561514","version":"1","preferredName":"Melanoma","longName":"2561514","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD57-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-05","modifiedBy":"COOPERM","dateModified":"2018-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B5B3-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029266","valueDescription":"Merkel Cell Carcinoma","ValueMeaning":{"publicId":"3210716","version":"1","preferredName":"Merkel Cell Carcinoma","longName":"3210716","preferredDefinition":"A rare malignant cutaneous tumor seen in elderly patients.  Its usual location is on the head, neck and extremities.  The tumor is composed of small round cells with scanty cytoplasm arranged in a trabecular pattern, or in ill-defined nodules or in a diffuse pattern.  The tumor cells contain cytoplasmic membrane-bound dense core granules resembling neurosecretory granules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Merkel Cell Carcinoma","conceptCode":"C9231","definition":"A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-935E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B5C7-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10040811","valueDescription":"Malignant Skin Neoplasm","ValueMeaning":{"publicId":"3210712","version":"1","preferredName":"Malignant Skin Neoplasm","longName":"3210712","preferredDefinition":"A primary or metastatic tumor involving the skin. Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes. Metastatic tumors to the skin include carcinomas and lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Skin Neoplasm","conceptCode":"C2920","definition":"A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-928C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B5DB-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10041834","valueDescription":"Skin Squamous Cell Carcinoma","ValueMeaning":{"publicId":"4722553","version":"1","preferredName":"Skin Squamous Cell Carcinoma","longName":"4722553","preferredDefinition":"A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Squamous Cell Carcinoma","conceptCode":"C4819","definition":"A carcinoma arising from the squamous cells of the epidermis.  Skin squamous cell carcinoma is most commonly found on sun-exposed areas.  The majority of the tumors are well-differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B5E9-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B602-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10001886","valueDescription":"Alveolar Soft Part Sarcoma","ValueMeaning":{"publicId":"3179234","version":"1","preferredName":"Alveolar Soft Part Sarcoma","longName":"3179234","preferredDefinition":"A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults the most common sites of involvement are the extremities, and in infants and children, the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alveolar Soft Part Sarcoma","conceptCode":"C3750","definition":"A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults the most common sites of involvement are the extremities, and in infants and children, the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CD57-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"ONEDATA","dateModified":"2010-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B616-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065865","valueDescription":"Clear Cell Sarcoma of Soft Tissue","ValueMeaning":{"publicId":"3179239","version":"1","preferredName":"Clear Cell Sarcoma of Soft Tissue","longName":"3179239","preferredDefinition":"A rare malignant neoplasm with melanocytic differentiation characterized by the presence of polygonal or spindle shaped clear cells. This sarcoma usually affects the tendons and aponeuroses and is associated with a poor prognosis due to recurrences and metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Sarcoma of Soft Tissue","conceptCode":"C3745","definition":"A rare malignant neoplasm with melanocytic differentiation characterized by the presence of polygonal or spindle shaped clear cells. This sarcoma usually affects the tendons and aponeuroses and is associated with a poor prognosis due to recurrences and metastases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CE10-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"ONEDATA","dateModified":"2010-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B62A-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10057043","valueDescription":"Dermatofibrosarcoma Protuberans","ValueMeaning":{"publicId":"3179341","version":"1","preferredName":"Dermatofibrosarcoma Protuberans","longName":"3179341","preferredDefinition":"An intermediate cutaneous fibrohistiocytic neoplasm, presenting as a nodular cutaneous mass, most often on the trunk and the proximal extremities.  The tumor diffusely infiltrates the dermis and the subcutaneous tissues.  It is considered a locally aggressive neoplasm, which often recurs but rarely metastasizes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dermatofibrosarcoma Protuberans","conceptCode":"C4683","definition":"A low grade fibroblastic neoplasm presenting as a nodular cutaneous mass, most often on the trunk and the proximal extremities.  The tumor diffusely infiltrates the dermis and the subcutaneous tissues.  It is considered a locally aggressive neoplasm, which often recurs but rarely metastasizes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-831C-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B63E-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10064587","valueDescription":"Desmoplastic Small Round Cell Tumor","ValueMeaning":{"publicId":"3179342","version":"1","preferredName":"Desmoplastic Small Round Cell Tumor","longName":"3179342","preferredDefinition":"An aggressive malignant neoplasm of uncertain lineage.  It is characterized by the presence of small round cells in a desmoplastic stroma.  It usually affects children and young adults.  The most common site of involvement is the abdomen.  Patients usually present with abdominal distention, pain, ascites, and a palpable abdominal mass.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoplastic Small Round Cell Tumor","conceptCode":"C8300","definition":"An aggressive malignant soft tissue neoplasm of uncertain differentiation.  It is characterized by a recurrent chromosomal translocation t(11;22)(p13;q12) and the presence of small round cells in a desmoplastic stroma.  It usually affects children and young adults.  The most common site of involvement is the abdomen.  Patients usually present with abdominal distention, pain, ascites, and a palpable abdominal mass.  The prognosis is usually poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-8341-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B652-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10016637","valueDescription":"Fibrosarcoma","ValueMeaning":{"publicId":"2568825","version":"1","preferredName":"Fibrosarcoma","longName":"2568825","preferredDefinition":"A malignant mesenchymal tumor affecting soft tissues and bone. It is classified as adult or infantile.  Infantile fibrosarcomas generally have a much more favorable prognosis than adult fibrosarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrosarcoma","conceptCode":"C3043","definition":"A malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9E6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B666-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10051066","valueDescription":"Gastrointestinal Stromal Tumor","ValueMeaning":{"publicId":"4265240","version":"1","preferredName":"Gastrointestinal Stromal Tumor","longName":"4265240","preferredDefinition":"A mesenchymal neoplasm most commonly seen in the gastrointestinal tract.  Cases involving tissues outside the gastrointestinal tract have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a specific KIT-expressing and KIT-signaling-driven mesenchymal tumor.  Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastrointestinal Stromal Tumor","conceptCode":"C3868","definition":"A stromal tumor most commonly seen in the gastrointestinal tract. Rare cases of solitary masses in the omentum or the mesentery have also been reported (extragastrointestinal gastrointestinal stromal tumor).  It is a tumor that differentiates along the lines of interstitial cells of Cajal.  Most cases contain KIT- or PDGFRA-activating mutations. Until recently, surgery has been the only effective therapy for this tumor.  However, many patients still experience recurrence.  Conventional chemotherapy and radiation therapy have been of limited value.  A KIT tyrosine kinase inhibitor, imatinib mesylate (also known as STI-571 or Gleevec), is now effective in the treatment of relapsed and unresectable cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-78B6-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B67A-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065870","valueDescription":"Atypical Teratoid/Rhabdoid Tumor","ValueMeaning":{"publicId":"4722554","version":"1","preferredName":"Atypical Teratoid/Rhabdoid Tumor","longName":"4722554","preferredDefinition":"An aggressive malignant embryonal neoplasm arising from the central nervous system.  It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  It may be associated with loss of chromosome 22.  The vast majority of cases occur in childhood.  Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor","conceptCode":"C6906","definition":"An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B6B7-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2024-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B6CF-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10035054","valueDescription":"Pineal parenchymal tumor","ValueMeaning":{"publicId":"4339096","version":"1","preferredName":"Pineal parenchymal tumor","longName":"4339096","preferredDefinition":"A neoplasm arising from the pineocyte, a cell with photosensory and neuroendocrine functions. It may be composed of mature elements or primitive, immature cells. The cellular composition determines the biological behavior and clinical outcome. Three types are recognized: pineoblastoma, pineocytoma, and pineal parenchymal tumor of intermediate differentiation (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineal Parenchymal Cell Neoplasm","conceptCode":"C6965","definition":"A neoplasm arising from the pineocyte, a cell with photosensory and neuroendocrine functions. It may be composed of mature elements or primitive, immature cells. The cellular composition determines the biological behavior and clinical outcome. Three types are recognized: pineoblastoma, pineocytoma, and pineal parenchymal tumor of intermediate differentiation (Adapted from WHO.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA902DE8-6A5E-3B83-E040-BB89AD432114","latestVersionIndicator":"Yes","beginDate":"2014-05-29","endDate":null,"createdBy":"PWEST","dateCreated":"2014-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B6DA-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10007959","valueDescription":"Primary Central Nervous System Neoplasm","ValueMeaning":{"publicId":"4722556","version":"1","preferredName":"Primary Central Nervous System Neoplasm","longName":"4722556","preferredDefinition":"A benign or malignant neoplasm that arises from the brain or the spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Central Nervous System Neoplasm","conceptCode":"C102871","definition":"A benign or malignant neoplasm that arises from the brain or the spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B6E7-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B700-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600120","valueDescription":"Choroid plexus carcinoma","ValueMeaning":{"publicId":"2578711","version":"1","preferredName":"Choroid plexus carcinoma","longName":"2578711","preferredDefinition":"Choroid Plexus Carcinoma (WHO grade III) is a malignant Choroid Plexus Tumor which shows anaplastic features and usually invades neighboring brain structures. CSF metastases are frequent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Carcinoma","conceptCode":"C4715","definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0084-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B70A-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600112","valueDescription":"Pilocytic astrocytoma","ValueMeaning":{"publicId":"2578708","version":"1","preferredName":"Pilocytic astrocytoma","longName":"2578708","preferredDefinition":"Pilocytic Astrocytoma, the most common glioma in children, is a WHO grade I astrocytic tumor. It is a generally well circumscribed, slowly growing, often cystic, astrocytoma. It is histologically characterized by a biphasic pattern with varying proportion of compacted bipolar cells which may have Rosenthal fibers (tapered corkscrew-shaped, brightly eosinophilic, intracytoplasmic hyaline masses) and loose textured multipolar cells with microcysts and granular bodies. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilocytic Astrocytoma","conceptCode":"C4047","definition":"A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0081-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B714-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10003571","valueDescription":"Diffuse astrocytoma","ValueMeaning":{"publicId":"2578704","version":"1","preferredName":"Diffuse astrocytoma","longName":"2578704","preferredDefinition":"A low-grade (WHO grade II) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Astrocytoma","conceptCode":"C7173","definition":"A low-grade (WHO grade 2) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-10","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B728-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065889","valueDescription":"Fibrillary astrocytoma","ValueMeaning":{"publicId":"2578707","version":"1","preferredName":"Fibrillary astrocytoma","longName":"2578707","preferredDefinition":"The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrillary Astrocytoma","conceptCode":"C4322","definition":"The most frequent histological variant of diffuse astrocytoma. It is predominantly composed of fibrillary neoplastic astrocytes. Nuclear atypia is a diagnostic criterion but mitotic activity, necrosis and microvascular proliferation are absent.  The occasional or regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis of fibrillary astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0080-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B732-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10008093","valueDescription":"High Grade Astrocytic Tumor","ValueMeaning":{"publicId":"4722558","version":"1","preferredName":"High Grade Astrocytic Tumor","longName":"4722558","preferredDefinition":"An anaplastic astrocytoma (grade III astrocytic tumor) or glioblastoma (grade IV astrocytic tumor).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Grade Astrocytic Tumor","conceptCode":"C102897","definition":"An astrocytic tumor exhibiting high-grade morphological characteristics. This category includes anaplastic astrocytoma, glioblastoma, and astrocytoma, IDH-mutant, grade 4.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B73F-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B758-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10006143","valueDescription":"Brain Stem Glioma","ValueMeaning":{"publicId":"4722559","version":"1","preferredName":"Brain Stem Glioma","longName":"4722559","preferredDefinition":"A neuroglial tumor that arises from the brain stem.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brain Stem Glioma","conceptCode":"C8501","definition":"A glioma that arises from the brain stem.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B764-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B77C-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10002224","valueDescription":"Anaplastic astrocytoma","ValueMeaning":{"publicId":"2572930","version":"1","preferredName":"Anaplastic astrocytoma","longName":"2572930","preferredDefinition":"A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Astrocytoma","conceptCode":"C9477","definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9EF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B787-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10006190","valueDescription":"Invasive Breast Carcinoma","ValueMeaning":{"publicId":"2581143","version":"1","preferredName":"Invasive Breast Carcinoma","longName":"2581143","preferredDefinition":"A carcinoma that infiltrates the breast parenchyma. The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU). Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ. It is the most common carcinoma affecting women. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma","conceptCode":"C9245","definition":"A carcinoma that infiltrates the breast parenchyma.  The vast majority are adenocarcinomas arising from the terminal ductal lobular unit (TDLU).  Often, the invasive adenocarcinoma co-exists with ductal or lobular carcinoma in situ.  It is the most common carcinoma affecting women.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A04-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B79B-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10021980","valueDescription":"Inflammatory Breast Carcinoma","ValueMeaning":{"publicId":"2558969","version":"1","preferredName":"Inflammatory Breast Carcinoma","longName":"2558969","preferredDefinition":"An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Inflammatory Carcinoma","conceptCode":"C4001","definition":"An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B366-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"TAYLORT","dateModified":"2017-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B7AF-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10024744","valueDescription":"Lobular Breast Carcinoma In Situ","ValueMeaning":{"publicId":"2581227","version":"1","preferredName":"Lobular Breast Carcinoma In Situ","longName":"2581227","preferredDefinition":"Lobular carcinoma in situ is characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. LCIS is frequently multifocal (90% in some series) and bilateral. LCIS seldom becomes invasive, however there is an increased risk of infiltrating ductal adenocarcinoma.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Lobular Carcinoma In Situ","conceptCode":"C4018","definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A58-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B7C3-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10013806","valueDescription":"Ductal Breast Carcinoma In Situ","ValueMeaning":{"publicId":"2581232","version":"1","preferredName":"Ductal Breast Carcinoma In Situ","longName":"2581232","preferredDefinition":"Ductal carcinoma in situ (DCIS) is a carcinoma entirely confined to the mammary ducts. There is no evidence of invasion of the basement membrane. Currently, DCIS is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS. --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma In Situ","conceptCode":"C2924","definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B7D7-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10053650","valueDescription":"Malignant Bone Neoplasm","ValueMeaning":{"publicId":"3210707","version":"1","preferredName":"Malignant Bone Neoplasm","longName":"3210707","preferredDefinition":"A primary or metastatic malignant neoplasm affecting the bones.  Representative examples of primary malignant bone neoplasms include osteosarcoma, chondrosarcoma, and Ewing sarcoma.  Primary malignant bone neoplasms most often affect children and adolescents.  Representative examples of metastatic malignant neoplasms to the bones include carcinomas arising from other anatomic sites and lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Bone Neoplasm","conceptCode":"C4016","definition":"A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-91E2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B7EB-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10048397","valueDescription":"Endometrioid Stromal Sarcoma","ValueMeaning":{"publicId":"4265242","version":"1","preferredName":"Endometrioid Stromal Sarcoma","longName":"4265242","preferredDefinition":"A malignant, infiltrating mesenchymal tumor arising from the uterine corpus, cervix, vagina, and the ovary. Based on its morphologic characteristics, it is classified as either a low grade or an undifferentiated (high grade) stromal sarcoma. The low grade endometrioid stromal sarcoma is characterized by the presence of oval to spindle-shape cells that resemble the cells of the endometrial stroma, without evidence of significant atypia and pleomorphism. Numerous small vessels are also present. The undifferentiated stromal sarcoma is characterized by an aggressive clinical course, the presence of significant cellular atypia, pleomorphism, and high mitotic activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Stromal Sarcoma","conceptCode":"C8973","definition":"A malignant mesenchymal neoplasm that affects the uterine corpus, and rarely, the ovaries, cervix, and vagina. In the uterine corpus it is classified as low grade or high grade endometrial stromal sarcoma. In the remainder of the anatomic sites it is classified as low grade endometrioid stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-7909-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B81C-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10014735","valueDescription":"Endometrial Endometrioid Adenocarcinoma","ValueMeaning":{"publicId":"3475265","version":"1","preferredName":"Endometrial Endometrioid Adenocarcinoma","longName":"3475265","preferredDefinition":"A primary endometrial adenocarcinoma composed of neoplastic cells that form complex glandular patterns associated with budding and branching of the neoplastic glands.  The neoplastic glands resemble those of the normal endometrium and may or may not be associated with sheet-like proliferation of malignant cells.  Endometrioid adenocarcinoma is the most commonly seen morphologic variant of endometrial adenocarcinoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Endometrioid Adenocarcinoma","conceptCode":"C6287","definition":"A primary endometrial adenocarcinoma composed of neoplastic cells that form complex glandular patterns associated with budding and branching of the neoplastic glands.  The neoplastic glands resemble those of the normal endometrium and may or may not be associated with sheet-like proliferation of malignant cells.  Endometrioid adenocarcinoma is the most commonly seen morphologic variant of endometrial adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D37D29-6B00-D1BD-E040-BB89AD4325DD","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-06-06","modifiedBy":"TSESU","dateModified":"2023-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B831-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10046799","valueDescription":"Uterine Corpus Leiomyosarcoma","ValueMeaning":{"publicId":"3179382","version":"1","preferredName":"Uterine Corpus Leiomyosarcoma","longName":"3179382","preferredDefinition":"An aggressive malignant smooth muscle neoplasm, arising from the uterine corpus.  It is characterized by a proliferation of neoplastic spindle cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Leiomyosarcoma","conceptCode":"C6340","definition":"An aggressive malignant smooth muscle neoplasm, arising from the uterine corpus.  It is characterized by a proliferation of neoplastic spindle cells.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98903582-4FD7-C5EF-E040-BB89AD431B68","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B845-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033700","valueDescription":"Endometrial Serous Adenocarcinoma","ValueMeaning":{"publicId":"3104169","version":"1","preferredName":"Endometrial Serous Adenocarcinoma","longName":"3104169","preferredDefinition":"A high grade, aggressive adenocarcinoma arising from the endometrium.  It is characterized by the presence of complex papillary patterns with cellular budding.  Atypical mitoses, necrosis, and psammoma bodies may be present.  It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia.  It tends to invade deeply into the myometrium and spreads into the lymphatic vessels.  Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Serous Adenocarcinoma","conceptCode":"C27838","definition":"A high-grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87E99CE1-B739-EEEA-E040-BB89AD43141F","latestVersionIndicator":"Yes","beginDate":"2010-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-31","modifiedBy":"COOPERM","dateModified":"2011-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B859-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10046804","valueDescription":"Malignant Uterine Neoplasm","ValueMeaning":{"publicId":"3210714","version":"1","preferredName":"Malignant Uterine Neoplasm","longName":"3210714","preferredDefinition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Uterine Neoplasm","conceptCode":"C3552","definition":"Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-92D0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B86D-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10046888","valueDescription":"Vaginal Carcinoma","ValueMeaning":{"publicId":"3125025","version":"1","preferredName":"Vaginal Carcinoma","longName":"3125025","preferredDefinition":"A carcinoma arising from the vaginal epithelium. The majority of vaginal carcinomas are squamous cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Carcinoma","conceptCode":"C3917","definition":"A carcinoma arising from the vaginal epithelium. The majority of vaginal carcinomas are squamous cell carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C8C84BA-753B-B840-E040-BB89AD4308AA","latestVersionIndicator":"Yes","beginDate":"2010-07-29","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B882-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10047743","valueDescription":"Vulvar Carcinoma","ValueMeaning":{"publicId":"3210732","version":"1","preferredName":"Vulvar Carcinoma","longName":"3210732","preferredDefinition":"A carcinoma arising from the vulva.  It usually affects elderly women but has been observed in premenopausal women as well.  The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora.  In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vulvar Carcinoma","conceptCode":"C4866","definition":"A carcinoma arising from the vulva.  It usually affects elderly women but has been observed in premenopausal women as well.  The most frequently seen histologic type is squamous cell carcinoma. The most common site of involvement is the labia majora.  In many cases, the development of vulvar cancer is preceded by condyloma or squamous dysplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9600-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B8BC-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025519","valueDescription":"Malignant Male Reproductive System Neoplasm","ValueMeaning":{"publicId":"4722578","version":"1","preferredName":"Malignant Male Reproductive System Neoplasm","longName":"4722578","preferredDefinition":"A primary or metastatic malignant neoplasm involving the male reproductive system.  Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Male Reproductive System Neoplasm","conceptCode":"C8561","definition":"A primary or metastatic malignant neoplasm involving the male reproductive system.  Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B8CA-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B8E3-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600236","valueDescription":"Paget Disease of the Penis","ValueMeaning":{"publicId":"4722580","version":"1","preferredName":"Paget Disease of the Penis","longName":"4722580","preferredDefinition":"A premalignant condition morphologically characterised by the presence of the characteristic Paget cells in the intraepithelial tissue of the penis.  It presents as a smooth raised reddish area that may or may not be painful. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penile Paget Disease","conceptCode":"C27817","definition":"A rare, slow-growing, usually non-invasive intraepithelial adenocarcinoma affecting the penile skin or mucosal surface. The malignant cells are large with abundant pale cytoplasm and vesicular nuclei with prominent nucleoli. (WHO 2016)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B8F0-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B909-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10034330","valueDescription":"Penile Carcinoma","ValueMeaning":{"publicId":"4722582","version":"1","preferredName":"Penile Carcinoma","longName":"4722582","preferredDefinition":"A carcinoma that arises from the penis. Risk factors include phimosis and human papillomavirus infection. The majority of penile carcinomas are squamous cell carcinomas. The most frequent clinical presentation is an irregular mass in the glans of the penis. Treatment includes surgical management and radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penile Carcinoma","conceptCode":"C9061","definition":"A carcinoma that arises from the penis. Risk factors include phimosis and human papillomavirus infection. The majority of penile carcinomas are squamous cell carcinomas. The most frequent clinical presentation is an irregular mass in the glans of the penis. Treatment includes surgical management and radiation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B916-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B92F-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10059631","valueDescription":"Squamous Cell Carcinoma of the Penis","ValueMeaning":{"publicId":"4722584","version":"1","preferredName":"Squamous Cell Carcinoma of the Penis","longName":"4722584","preferredDefinition":"A squamous cell carcinoma arising from the penis.  It occurs chiefly in the squamous epithelium of the glans, coronal sulcus, and foreskin.  Etiologic factors include phimosis, lichen sclerosus, smoking, ultraviolet irradiation, history of warts or condylomas, and lack of circumcision.  Human papilloma virus is present in a subset of penile squamous cell carcinomas.  Patients may present with an exophytic or flat ulcerative mass in the glans or a large primary tumor with inguinal nodal and skin metastases.  Morphologic variants include the basaloid carcinoma, warty (condylomatous) carcinoma, verrucous carcinoma, and sarcomatoid (spindle cell) carcinoma. (WHO, 2004)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penile Squamous Cell Carcinoma","conceptCode":"C7729","definition":"A squamous cell carcinoma arising from the penis.  It occurs chiefly in the squamous epithelium of the glans, coronal sulcus, and foreskin.  Etiologic factors include phimosis, lichen sclerosus, smoking, ultraviolet irradiation, history of warts or condylomas, and lack of circumcision.  Human papilloma virus is present in a subset of penile squamous cell carcinomas.  Patients may present with an exophytic or flat ulcerative mass in the glans or a large primary tumor with inguinal nodal and skin metastases. (WHO, 2004)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B93C-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B955-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10036910","valueDescription":"Prostate Carcinoma","ValueMeaning":{"publicId":"2596646","version":"1","preferredName":"Prostate Carcinoma","longName":"2596646","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2962D840-ED32-4EC3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B95F-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10036912","valueDescription":"Prostatic Intraepithelial Neoplasia","ValueMeaning":{"publicId":"3250499","version":"1","preferredName":"Prostatic Intraepithelial Neoplasia","longName":"3250499","preferredDefinition":"A neoplastic proliferation of the epithelial cells that line the acini and the ducts of the prostate gland.  The neoplastic epithelial cells are confined within the acini and the ducts and they do not invade the surrounding prostatic stroma.  Morphologically, it is classified as low or high grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostatic Intraepithelial Neoplasia","conceptCode":"C4064","definition":"A neoplastic proliferation of the epithelial cells that line the acini and the ducts of the prostate gland.  The neoplastic epithelial cells are confined within the acini and the ducts and they do not invade the surrounding prostatic stroma.  Morphologically, it is classified as low or high grade.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6F215E6-C6B8-B293-E040-BB89AD432EF3","latestVersionIndicator":"Yes","beginDate":"2011-06-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B973-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033272","valueDescription":"Malignant Ovarian Neoplasm","ValueMeaning":{"publicId":"3210710","version":"1","preferredName":"Malignant Ovarian Neoplasm","longName":"3210710","preferredDefinition":"A primary or metastatic malignant tumor involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ovarian Neoplasm","conceptCode":"C7431","definition":"A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9248-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B997-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033159","valueDescription":"Ovarian Carcinoma","ValueMeaning":{"publicId":"2593147","version":"1","preferredName":"Ovarian Carcinoma","longName":"2593147","preferredDefinition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Carcinoma","conceptCode":"C4908","definition":"A malignant neoplasm originating from the surface ovarian epithelium.  It accounts for the greatest number of deaths from malignancies of the female genital tract and is the fifth leading cause of cancer fatalities in women.  It is predominantly a disease of older white women of northern European extraction, but it is seen in all ages and ethnic groups.  Adenocarcinomas constitute the vast majority of ovarian carcinomas.  The pattern of metastatic spread in ovarian carcinoma is similar regardless of the microscopic type.  The most common sites of involvement are the contralateral ovary, peritoneal cavity, para-aortic and pelvic lymph nodes, and liver.  Lung and pleura are the most common sites of extra-abdominal spread.  The primary form of therapy is surgical.  The overall prognosis of ovarian carcinoma remains poor, a direct result of its rapid growth rate and the lack of early symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E43-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"COOPERM","dateModified":"2019-02-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B9AC-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065858","valueDescription":"Malignant Ovarian Surface Epithelial-Stromal Tumor","ValueMeaning":{"publicId":"4722586","version":"1","preferredName":"Malignant Ovarian Surface Epithelial-Stromal Tumor","longName":"4722586","preferredDefinition":"An invasive malignant neoplasm that originates from the surface epithelium of the ovary.  It is composed of malignant epithelial cells and stroma.  Representative examples include serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma, and malignant Brenner tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Ovarian Epithelial Tumor","conceptCode":"C40026","definition":"An invasive malignant tumor that originates from the surface epithelium of the ovary.  It is composed of malignant epithelial cells and stroma.  Representative examples include serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, clear cell adenocarcinoma, and malignant Brenner tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B9B9-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B9D2-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10026669","valueDescription":"Primary Peritoneal Carcinoma","ValueMeaning":{"publicId":"4722587","version":"1","preferredName":"Primary Peritoneal Carcinoma","longName":"4722587","preferredDefinition":"A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary.  Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively.  The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Peritoneal Carcinoma","conceptCode":"C40022","definition":"A rare carcinoma that arises from the peritoneum and resembles the malignant surface epithelial-stromal tumors that arise from the ovary.  Serous adenocarcinoma is the most common histologic variant. It affects women almost exclusively.  The diagnosis of primary peritoneal carcinoma can be made only if both ovaries are not involved by tumor, or, if the ovaries are involved, the tumor is confined to the ovarian surface without invasion of the ovarian stroma and the peritoneal involvement is greater than the ovarian surface involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-B9DC-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-B9F4-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10007508","valueDescription":"Uterine Carcinosarcoma","ValueMeaning":{"publicId":"3179372","version":"1","preferredName":"Uterine Carcinosarcoma","longName":"3179372","preferredDefinition":"A usually aggressive malignant neoplasm arising from the uterine corpus and less often the cervix.  It is characterized by the presence of two components: a malignant epithelial component and a sarcomatous component.  In the uterine corpus the epithelial component is usually glandular whereas in the cervix is usually non-glandular.  Carcinosarcoma of the cervix, although it is aggressive, it may have a better prognosis compared to the uterine corpus carcinosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Carcinosarcoma","conceptCode":"C42700","definition":"A usually aggressive malignant neoplasm arising from the uterine corpus and less often the cervix.  It is characterized by the presence of two components: a malignant epithelial component and a sarcomatous component.  In the uterine corpus the epithelial component is usually glandular whereas in the cervix is usually non-glandular.  Carcinosarcoma of the cervix, although it is aggressive, it may have a better prognosis compared to the uterine corpus carcinosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-87CE-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BA09-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029000","valueDescription":"Solid Tumor","ValueMeaning":{"publicId":"4264994","version":"1","preferredName":"Solid Tumor","longName":"4264994","preferredDefinition":"An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3F94-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BA1E-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10055031","valueDescription":"Vascular Neoplasm","ValueMeaning":{"publicId":"4722589","version":"1","preferredName":"Vascular Neoplasm","longName":"4722589","preferredDefinition":"A benign or malignant neoplasm arising from vascular tissue including arteries, veins, venous sinuses, arterioles and capillaries. It may occur in essentially any body location and is characterized by the presence of vascular channel formation and endothelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vascular Neoplasm","conceptCode":"C7388","definition":"A benign, intermediate, or malignant neoplasm arising from vascular tissue including arteries, veins, venous sinuses, lymphatic vessels, arterioles and capillaries. It may occur in essentially any body location and is characterized by the presence of vascular channel formation and endothelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BA2C-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BA45-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600296","valueDescription":"Non-Neoplastic Disorder","ValueMeaning":{"publicId":"4264955","version":"1","preferredName":"Non-Neoplastic Disorder","longName":"4264955","preferredDefinition":"Any disorder other than abnormal tissue growth resulting from uncontrolled cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Neoplastic Disorder","conceptCode":"C53529","definition":"Any disorder other than abnormal tissue growth resulting from uncontrolled cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3A43-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BA59-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10008224","valueDescription":"Cervical Adenocarcinoma","ValueMeaning":{"publicId":"4722591","version":"1","preferredName":"Cervical Adenocarcinoma","longName":"4722591","preferredDefinition":"An adenocarcinoma arising from the cervical epithelium. It accounts for approximately 15% of invasive cervical carcinomas. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors. Grossly, advanced cervical adenocarcinoma may present as an exophytic mass, an ulcerated lesion, or diffuse cervical enlargement. Microscopically, the majority of cervical adenocarcinomas are of the endocervical (mucinous) type.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Adenocarcinoma","conceptCode":"C4029","definition":"An adenocarcinoma arising from the endocervical glandular epithelium. It is classified as either human papillomavirus-related or human papillomavirus-independent adenocarcinoma. Histologic variants include usual-type, mucinous, mesonephric, serous, clear cell, and endometrioid adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BA67-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BA80-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10008238","valueDescription":"Cervical Carcinoma","ValueMeaning":{"publicId":"4722592","version":"1","preferredName":"Cervical Carcinoma","longName":"4722592","preferredDefinition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma and undifferentiated carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Carcinoma","conceptCode":"C9039","definition":"A carcinoma arising from either the exocervical squamous epithelium or the endocervical glandular epithelium. The major histologic types of cervical carcinoma are squamous cell carcinoma and adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BA8A-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BAA2-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10041848","valueDescription":"Cervical Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3521937","version":"1","preferredName":"Cervical Squamous Cell Carcinoma","longName":"3521937","preferredDefinition":"A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: Conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Squamous Cell Carcinoma","conceptCode":"C4028","definition":"A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C47BC307-6801-000B-E040-BB89AD43320C","latestVersionIndicator":"Yes","beginDate":"2012-07-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-07-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BAB7-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10059383","valueDescription":"Cervical Intraepithelial Neoplasia","ValueMeaning":{"publicId":"3248580","version":"1","preferredName":"Cervical Intraepithelial Neoplasia","longName":"3248580","preferredDefinition":"Squamous or glandular intraepithelial neoplasia that affects the cervical mucosal epithelium. There is no evidence of stromal invasion. According to the degree of cellular atypia and the associated architectural changes, it is classified as low or high grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cervical Intraepithelial Neoplasia","conceptCode":"C3782","definition":"Squamous or glandular intraepithelial neoplasia that affects the cervical mucosal epithelium. There is no evidence of stromal invasion. According to the degree of cellular atypia and the associated architectural changes, it is classified as low or high grade.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BEED-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BACB-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10016411","valueDescription":"Malignant Female Reproductive System Neoplasm","ValueMeaning":{"publicId":"4722593","version":"1","preferredName":"Malignant Female Reproductive System Neoplasm","longName":"4722593","preferredDefinition":"Cancer of the female reproductive tract, including the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Female Reproductive System Neoplasm","conceptCode":"C4913","definition":"A primary or metastatic malignant neoplasm involving the female reproductive system.  Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BAD7-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BAF0-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10018212","valueDescription":"Gestational Trophoblastic Tumor","ValueMeaning":{"publicId":"4722594","version":"1","preferredName":"Gestational Trophoblastic Tumor","longName":"4722594","preferredDefinition":"A group of interrelated trophoblastic diseases arising from pregnancy. They are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gestational Trophoblastic Tumor","conceptCode":"C4699","definition":"A diverse group of pregnancy-related tumors characterized by excessive proliferation of trophoblasts. It includes gestational choriocarcinoma, epithelioid trophoblastic tumor, placental site trophoblastic tumor, and mixed trophoblastic tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F886EE6-BAFA-DB60-E050-BB89AD4356E3","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BB13-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10058354","valueDescription":"Bronchioloalveolar Carcinoma","ValueMeaning":{"publicId":"2837829","version":"1","preferredName":"Bronchioloalveolar Carcinoma","longName":"2837829","preferredDefinition":"A well or moderately differentiated morphologic variant of lung adenocarcinoma characterized by tumor growth along the alveolar structures without stromal, vascular, or pleural invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimally Invasive Lung Adenocarcinoma","conceptCode":"C2923","definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-47D8-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BB64-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025032","valueDescription":"Lung Adenocarcinoma","ValueMeaning":{"publicId":"3106713","version":"1","preferredName":"Lung Adenocarcinoma","longName":"3106713","preferredDefinition":"A carcinoma characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Adenocarcinoma","conceptCode":"C3512","definition":"A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells.  There is a male predilection with a male to female ratio of 2:1.  Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding.  If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever.  Tobacco smoke is a known risk factor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-0D4B-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BB79-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600324","valueDescription":"Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components","ValueMeaning":{"publicId":"3248503","version":"1","preferredName":"Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components","longName":"3248503","preferredDefinition":"A lung adenocarcinoma consisting of a bronchioloalveolar component and an invasive adenocarcinomatous component.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Adenocarcinoma with Mixed Bronchioloalveolar and Invasive Components","conceptCode":"C65197","definition":"A lung adenocarcinoma consisting of a bronchioloalveolar component and an invasive adenocarcinomatous component.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B8531E-18DA-F891-E040-BB89AD4324F8","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BB8E-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029514","valueDescription":"Non-Small Cell Lung Carcinoma","ValueMeaning":{"publicId":"2581628","version":"1","preferredName":"Non-Small Cell Lung Carcinoma","longName":"2581628","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.  Non-small cell lung carcinomas have a poor response to conventional chemotherapy.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BBA2-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025126","valueDescription":"Squamous Cell Lung Carcinoma","ValueMeaning":{"publicId":"2956083","version":"1","preferredName":"Squamous Cell Lung Carcinoma","longName":"2956083","preferredDefinition":"A carcinoma arising from malignant squamous bronchial epithelial cells and characterized by the presence of keratinization and/or intercellular bridges.  Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Squamous Cell Carcinoma","conceptCode":"C3493","definition":"A carcinoma arising from squamous bronchial epithelial cells. It may be keratinizing or non-keratinizing. Keratinizing squamous cell carcinoma is characterized by the presence of keratinization, pearl formation, and/or intercellular bridges. Non-keratinizing squamous cell carcinoma is characterized by the absence of keratinization, pearl formation, and intercellular bridges. Cigarette smoking and arsenic exposure are strongly associated with squamous cell lung carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76EBECE2-B835-A0E2-E040-BB89AD435984","latestVersionIndicator":"Yes","beginDate":"2009-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BBB6-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10041071","valueDescription":"Small Cell Lung Carcinoma","ValueMeaning":{"publicId":"3297699","version":"1","preferredName":"Small Cell Lung Carcinoma","longName":"3297699","preferredDefinition":"A highly aggressive subtype of lung carcinoma characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Small Cell Carcinoma","conceptCode":"C4917","definition":"A highly aggressive carcinoma with neuroendocrine differentiation arising from the lung. It is characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B035F07A-837C-9251-E040-BB89AD4303FC","latestVersionIndicator":"Yes","beginDate":"2011-10-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-26","modifiedBy":"FINCHAMB","dateModified":"2024-01-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BBC0-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10001166","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2567203","version":"1","preferredName":"Adenocarcinoma","longName":"2567203","preferredDefinition":"A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D390-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F886EE6-BBD4-DB60-E050-BB89AD4356E3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600336","valueDescription":"Monomorphic Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"4722713","version":"1","preferredName":"Monomorphic Post-Transplant Lymphoproliferative Disorder","longName":"4722713","preferredDefinition":"A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monomorphic Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7233","definition":"A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C304-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8A20-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10053130","valueDescription":"Breast Phyllodes Tumor","ValueMeaning":{"publicId":"4722822","version":"1","preferredName":"Breast Phyllodes Tumor","longName":"4722822","preferredDefinition":"A benign, malignant, or borderline circumscribed biphasic neoplasm that arises from the breast.  It usually affects middle-aged women.  It is characterized by the presence of a double layer of epithelial cells that are arranged in clefts, surrounded by a spindle cell mesenchymal (stromal) component.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Phyllodes Tumor","conceptCode":"C7575","definition":"A benign, malignant, or borderline circumscribed biphasic neoplasm that arises from the breast.  It usually affects middle-aged women.  It is characterized by the presence of a double layer of epithelial cells that are arranged in clefts, surrounded by a spindle cell mesenchymal (stromal) component.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8A2D-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8A46-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10043342","valueDescription":"Malignant Testicular Germ Cell Tumor","ValueMeaning":{"publicId":"2672904","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor","longName":"2672904","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Germ Cell Tumor","conceptCode":"C9063","definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D5FE1C-A5B6-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8A5A-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033268","valueDescription":"Borderline Ovarian Surface Epithelial-Stromal Tumor","ValueMeaning":{"publicId":"4722824","version":"1","preferredName":"Borderline Ovarian Surface Epithelial-Stromal Tumor","longName":"4722824","preferredDefinition":"An epithelial tumor arising from the ovary without definitive morphologic characteristics of malignancy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Borderline Ovarian Epithelial Tumor","conceptCode":"C4783","definition":"A low grade epithelial tumor arising from the ovary. It is characterized by an atypical proliferation of epithelial cells. There is no evidence of stromal invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8A67-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8A80-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10026659","valueDescription":"Anaplastic oligodendroglioma","ValueMeaning":{"publicId":"2572933","version":"1","preferredName":"Anaplastic oligodendroglioma","longName":"2572933","preferredDefinition":"A WHO grade III oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligodendroglioma","conceptCode":"C4326","definition":"A WHO grade 3 oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8A8A-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10018337","valueDescription":"Glioblastoma multiforme","ValueMeaning":{"publicId":"2831120","version":"1","preferredName":"Glioblastoma multiforme","longName":"2831120","preferredDefinition":"The most malignant astrocytic tumor (WHO grade IV).  It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma). Two histologic variants are recognized: giant cell glioblastoma and gliosarcoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D4F-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8A94-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10007953","valueDescription":"Central Nervous System Lymphoma","ValueMeaning":{"publicId":"2573501","version":"1","preferredName":"Central Nervous System Lymphoma","longName":"2573501","preferredDefinition":"Cancer that arises in the lymphoid tissue found in the central nervous system (CNS). The CNS includes the brain and spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Lymphoma","conceptCode":"C9301","definition":"A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8AA8-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10006285","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"3589907","version":"1","preferredName":"Breast Carcinoma","longName":"3589907","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9FF059F-8BC9-73AE-E040-BB89AD4367D2","latestVersionIndicator":"Yes","beginDate":"2012-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8ABC-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10000884","valueDescription":"Acute Myeloid Leukemia Not Otherwise Specified","ValueMeaning":{"publicId":"4722783","version":"1","preferredName":"Acute Myeloid Leukemia Not Otherwise Specified","longName":"4722783","preferredDefinition":"This term refers to acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  It includes entities classified according to the French-American-British classification scheme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Not Otherwise Specified","conceptCode":"C27753","definition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-22E7-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8AD1-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600340","valueDescription":"Post-Transplant Lymphoproliferative Disorder, Early Lesion","ValueMeaning":{"publicId":"4722829","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder, Early Lesion","longName":"4722829","preferredDefinition":"A lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by the lack of tissue destruction and the architectural preservation of the involved tissues.  It includes two morphologic variants: plasmacytic hyperplasia and infectious mononucleosis-like lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Destructive Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7234","definition":"A lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by the lack of tissue destruction and the architectural preservation of the involved tissues.  It includes two morphologic variants: plasmacytic hyperplasia and infectious mononucleosis-like lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8C8F0D-8B45-02A0-E050-BB89AD430E17","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8C8F0D-8B5E-02A0-E050-BB89AD430E17","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029145","valueDescription":"Wilms Tumor","ValueMeaning":{"publicId":"2593188","version":"1","preferredName":"Wilms Tumor","longName":"2593188","preferredDefinition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wilms Tumor","conceptCode":"C3267","definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28701A35-66BA-579B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3A75-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025065","valueDescription":"Lung Carcinoma","ValueMeaning":{"publicId":"4722609","version":"1","preferredName":"Lung Carcinoma","longName":"4722609","preferredDefinition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A5000-3A7F-67E5-E050-BB89AD433CEA","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3A97-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10043673","valueDescription":"thymoma","ValueMeaning":{"publicId":"2579823","version":"1","preferredName":"thymoma","longName":"2579823","preferredDefinition":"A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant and probably not neoplastic. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (Stedman, 25th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thymoma","conceptCode":"C3411","definition":"A neoplasm arising from the epithelial cells of the thymus.  Although thymomas are usually encapsulated tumors, they may invade the capsule and infiltrate the surrounding tissues or even metastasize to distant anatomic sites.  The following morphologic subtypes are currently recognized: type A, type B, type AB, metaplastic, micronodular, microscopic, and sclerosing thymoma.  Thymomas type B are further subdivided into types B1, B2, and B3. Thymoma type B3 usually has the most aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-04DC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3AAC-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027410","valueDescription":"Mesothelioma","ValueMeaning":{"publicId":"3292894","version":"1","preferredName":"Mesothelioma","longName":"3292894","preferredDefinition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesothelioma","conceptCode":"C3234","definition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AEB9CA2C-4514-D4C6-E040-BB89AD432205","latestVersionIndicator":"Yes","beginDate":"2011-10-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3AB6-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10009253","valueDescription":"Clear Cell Sarcoma of the Kidney","ValueMeaning":{"publicId":"3210697","version":"1","preferredName":"Clear Cell Sarcoma of the Kidney","longName":"3210697","preferredDefinition":"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. This type of sarcoma frequently metastasizes to the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Sarcoma of the Kidney","conceptCode":"C4264","definition":"A rare pediatric sarcoma affecting the kidney. It is characterized by the presence of epithelioid or spindle cells forming cords or nests, separated by fibrovascular septa. It metastasizes to lung, bone, brain and soft tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-8FFE-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3AF8-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10038485","valueDescription":"Renal Carcinoma","ValueMeaning":{"publicId":"4722613","version":"1","preferredName":"Renal Carcinoma","longName":"4722613","preferredDefinition":"A carcinoma arising from the epithelium of the renal parenchyma (renal cell carcinoma) or the renal pelvis (renal pelvis carcinoma).  The vast majority of renal cell carcinomas are adenocarcinomas.  The vast majority of renal pelvis carcinomas are transitional cell carcinomas.  Renal carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kidney Carcinoma","conceptCode":"C9384","definition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A5000-3B02-67E5-E050-BB89AD433CEA","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3B1B-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10066351","valueDescription":"Carcinoma of the Collecting Ducts of Bellini","ValueMeaning":{"publicId":"2581666","version":"1","preferredName":"Carcinoma of the Collecting Ducts of Bellini","longName":"2581666","preferredDefinition":"Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Collecting Duct Carcinoma","conceptCode":"C6194","definition":"Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-09","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-09","modifiedBy":"COOPERM","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3B2F-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033702","valueDescription":"Papillary Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581626","version":"1","preferredName":"Papillary Renal Cell Carcinoma","longName":"2581626","preferredDefinition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Renal Cell Carcinoma","conceptCode":"C6975","definition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3B43-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10066352","valueDescription":"Sarcomatoid Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581627","version":"1","preferredName":"Sarcomatoid Renal Cell Carcinoma","longName":"2581627","preferredDefinition":"A high grade carcinoma of the kidney.  It is not a distinct clinicopathological entity and includes a diverse group of renal cell carcinomas which have been transformed from a lower to a higher grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcomatoid Renal Cell Carcinoma","conceptCode":"C27893","definition":"A high grade carcinoma of the kidney.  It is not a distinct clinicopathological entity and includes a diverse group of renal cell carcinomas which have been transformed from a lower to a higher grade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"COOPERM","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3B57-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10009251","valueDescription":"Clear Cell Renal Cell Carcinoma","ValueMeaning":{"publicId":"3248533","version":"1","preferredName":"Clear Cell Renal Cell Carcinoma","longName":"3248533","preferredDefinition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Renal Cell Carcinoma","conceptCode":"C4033","definition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-B9CF-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3B6C-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10038415","valueDescription":"Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581668","version":"1","preferredName":"Renal Cell Carcinoma","longName":"2581668","preferredDefinition":"Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C11-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-09","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-09","modifiedBy":"ONEDATA","dateModified":"2006-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3B76-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10039019","valueDescription":"Rhabdoid Tumor of the Kidney","ValueMeaning":{"publicId":"3210727","version":"1","preferredName":"Rhabdoid Tumor of the Kidney","longName":"3210727","preferredDefinition":"A rhabdoid tumor that arises from the kidney.  It occurs in children and it is associated with abnormalities of chromosome 22. It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdoid Tumor of the Kidney","conceptCode":"C8715","definition":"A rhabdoid tumor that arises from the kidney.  It occurs in children and it is associated with abnormalities of chromosome 22. It is characterized by the presence of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm.  The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9526-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A5000-3B8A-67E5-E050-BB89AD433CEA","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10007423","valueDescription":"Carcinoma","ValueMeaning":{"publicId":"2935533","version":"1","preferredName":"Carcinoma","longName":"2935533","preferredDefinition":"A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71F88553-C4BB-17CC-E040-BB89AD43398B","latestVersionIndicator":"Yes","beginDate":"2009-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F8A9-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10024233","valueDescription":"Metastatic Malignant Neoplasm in the Leptomeninges","ValueMeaning":{"publicId":"4722599","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Leptomeninges","longName":"4722599","preferredDefinition":"A serious problem that may occur in cancer in which cancer cells spread from the original (primary) tumor to the meninges (thin layers of tissue that cover and protect the brain and spinal cord). It can happen in many types of cancer, but is the most common in melanoma, breast, lung, and gastrointestinal cancer. The cancer may cause the meninges to be inflamed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Leptomeninges","conceptCode":"C3814","definition":"A malignant neoplasm that has spread from its original site of growth to the leptomeninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F8B3-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F8CC-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025538","valueDescription":"Malignant Ascites","ValueMeaning":{"publicId":"4265267","version":"1","preferredName":"Malignant Ascites","longName":"4265267","preferredDefinition":"Accumulation of fluid in the peritoneal cavity resulting from the growth of primary or metastatic malignant neoplasms in the peritoneum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peritoneal Effusion","conceptCode":"C3815","definition":"Accumulation of fluid in the peritoneal cavity resulting from the growth of primary or metastatic malignant neoplasms in the peritoneum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4DE0-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F8E0-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027452","valueDescription":"Metastatic Malignant Neoplasm to the Bone","ValueMeaning":{"publicId":"2857211","version":"1","preferredName":"Metastatic Malignant Neoplasm to the Bone","longName":"2857211","preferredDefinition":"Cancer that has spread from the original (primary) tumor to the bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Bone","conceptCode":"C3580","definition":"The spread of a malignant neoplasm from a primary site to the skeletal system.  The majority of metastatic neoplasms to the bone are carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"661EB49B-B2D9-7D2B-E040-BB89AD4340DC","latestVersionIndicator":"Yes","beginDate":"2009-03-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F8F5-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10059282","valueDescription":"Metastatic Malignant Neoplasm in the Brain","ValueMeaning":{"publicId":"4722600","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Brain","longName":"4722600","preferredDefinition":"A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Brain","conceptCode":"C3813","definition":"A malignant neoplasm that has spread to the brain from another anatomic site or system. The majority are carcinomas (usually lung or breast carcinomas).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F900-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F919-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027457","valueDescription":"Metastatic Malignant Neoplasm in the Liver","ValueMeaning":{"publicId":"4722601","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Liver","longName":"4722601","preferredDefinition":"A malignant neoplasm that has spread to the liver from another (primary) anatomic site.  Such malignant neoplasms may be carcinomas, lymphomas, melanomas, or sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Liver","conceptCode":"C4758","definition":"A malignant neoplasm that has spread to the liver from another (primary) anatomic site. Representative examples include carcinomas, lymphomas, melanomas, or sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F923-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F93C-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027458","valueDescription":"Metastatic Malignant Neoplasm in the Lung","ValueMeaning":{"publicId":"4722602","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Lung","longName":"4722602","preferredDefinition":"The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Lung","conceptCode":"C3577","definition":"The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F946-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F95F-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10051676","valueDescription":"Metastatic Malignant Neoplasm in the Peritoneum","ValueMeaning":{"publicId":"4722603","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Peritoneum","longName":"4722603","preferredDefinition":"The spread of a malignant neoplasm to the peritoneum from another primary anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Peritoneum","conceptCode":"C4583","definition":"The spread of a malignant neoplasm to the peritoneum from another primary anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F969-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F982-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027465","valueDescription":"Metastatic Malignant Neoplasm in the Skin","ValueMeaning":{"publicId":"4722605","version":"1","preferredName":"Metastatic Malignant Neoplasm in the Skin","longName":"4722605","preferredDefinition":"The spread of a malignant neoplasm to the skin.  This may be from a primary skin malignant neoplasm, or from a malignant neoplasm at a distant site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Malignant Neoplasm in the Skin","conceptCode":"C5629","definition":"The spread of a malignant neoplasm to the skin.  This may be from a primary skin malignant neoplasm, or from a malignant neoplasm at a distant site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F98F-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F9A8-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10026673","valueDescription":"Pleural Effusion","ValueMeaning":{"publicId":"4264940","version":"1","preferredName":"Pleural Effusion","longName":"4264940","preferredDefinition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleural Effusion","conceptCode":"C3331","definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-37A4-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F9BC-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025691","valueDescription":"Miscellaneous Neoplasm","ValueMeaning":{"publicId":"4722607","version":"1","preferredName":"Miscellaneous Neoplasm","longName":"4722607","preferredDefinition":"A benign or malignant neoplasm which is not further characterized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Miscellaneous Neoplasm","conceptCode":"C102883","definition":"A benign or malignant neoplasm which is not further characterized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A2532-F9CA-F227-E050-BB89AD433E96","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F9E3-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10016180","valueDescription":"Fallopian Tube Carcinoma","ValueMeaning":{"publicId":"3210700","version":"1","preferredName":"Fallopian Tube Carcinoma","longName":"3210700","preferredDefinition":"A carcinoma arising from the fallopian tube which is attached to the uterine corpus (uterine body). Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fallopian Tube Carcinoma","conceptCode":"C3867","definition":"A carcinoma arising from the fallopian tube. Most patients are postmenopausal, and postmenopausal bleeding is the most frequently seen symptom. Morphologically, the majority of fallopian tube carcinomas are serous or endometrioid adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9080-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A2532-F9F7-F227-E050-BB89AD433E96","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033612","valueDescription":"Pancreatic Carcinoma","ValueMeaning":{"publicId":"2672905","version":"1","preferredName":"Pancreatic Carcinoma","longName":"2672905","preferredDefinition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Carcinoma","conceptCode":"C3850","definition":"A carcinoma arising from the exocrine pancreas. The overwhelming majority of pancreatic carcinomas are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D5FE1C-A62B-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1CC5-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065908","valueDescription":"Pancreatic Cystadenocarcinoma","ValueMeaning":{"publicId":"4722722","version":"1","preferredName":"Pancreatic Cystadenocarcinoma","longName":"4722722v1.00","preferredDefinition":"A cystic adenocarcinoma that arises from the pancreas. It includes the acinar cell and serous cystadenocarcinoma subtypes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Cystadenocarcinoma","conceptCode":"C3874","definition":"A cystic adenocarcinoma that arises from the pancreas. It includes the acinar cell and serous cystadenocarcinoma subtypes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1CD2-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1CEB-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10052747","valueDescription":"Pancreatic Adenocarcinoma","ValueMeaning":{"publicId":"4722723","version":"1","preferredName":"Pancreatic Adenocarcinoma","longName":"4722723","preferredDefinition":"An adenocarcinoma which arises from the exocrine pancreas.  Ductal adenocarcinoma and its variants are the most common types of pancreatic adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Adenocarcinoma","conceptCode":"C8294","definition":"An adenocarcinoma which arises from the exocrine pancreas.  Ductal adenocarcinoma and its variants are the most common types of pancreatic adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1CF7-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1D10-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10019810","valueDescription":"Liver and Intrahepatic Bile Duct Carcinoma","ValueMeaning":{"publicId":"4722724","version":"1","preferredName":"Liver and Intrahepatic Bile Duct Carcinoma","longName":"4722724","preferredDefinition":"Primary liver cancer is cancer that forms in the tissues of the liver. Secondary liver cancer is cancer that spreads to the liver from another part of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liver and Intrahepatic Bile Duct Carcinoma","conceptCode":"C7927","definition":"A carcinoma that arises from the hepatocytes or intrahepatic bile ducts.  The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1D1A-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1D33-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10049010","valueDescription":"Hepatocellular Carcinoma","ValueMeaning":{"publicId":"2573454","version":"1","preferredName":"Hepatocellular Carcinoma","longName":"2573454","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CHILLIJ","dateModified":"2007-03-27","changeDescription":"03/27/2007 - Updated with NCI Thesaurus definition (abbreviated version.)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1D47-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10019822","valueDescription":"Hepatoblastoma","ValueMeaning":{"publicId":"4264913","version":"1","preferredName":"Hepatoblastoma","longName":"4264913","preferredDefinition":"A malignant liver neoplasm that occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component that may be undifferentiated or develop into bone or cartilage. The treatment of choice for hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatoblastoma","conceptCode":"C3728","definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F3F28-FD89-6FE9-E040-BB89AD433764","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1D5B-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10017618","valueDescription":"Gallbladder Carcinoma","ValueMeaning":{"publicId":"3210701","version":"1","preferredName":"Gallbladder Carcinoma","longName":"3210701","preferredDefinition":"A malignant tumor arising from the epithelium of the gallbladder. It is associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gallbladder Carcinoma","conceptCode":"C3844","definition":"A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-90A2-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1D70-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10004669","valueDescription":"Cholangiocarcinoma","ValueMeaning":{"publicId":"4722725","version":"1","preferredName":"Cholangiocarcinoma","longName":"4722725","preferredDefinition":"A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cholangiocarcinoma","conceptCode":"C4436","definition":"A carcinoma that arises from the intrahepatic bile ducts, the hepatic ducts, or the common bile duct distal to the insertion of the cystic duct. The vast majority of tumors are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1D7B-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1D93-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10017986","valueDescription":"Malignant Digestive System Neoplasm","ValueMeaning":{"publicId":"4722726","version":"1","preferredName":"Malignant Digestive System Neoplasm","longName":"4722726","preferredDefinition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Digestive System Neoplasm","conceptCode":"C4890","definition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1D9E-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1DB7-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10030186","valueDescription":"Esophageal Squamous Cell Carcinoma","ValueMeaning":{"publicId":"4722729","version":"1","preferredName":"Esophageal Squamous Cell Carcinoma","longName":"4722729","preferredDefinition":"A squamous cell carcinoma arising from the esophagus.  It is associated with a long history of tobacco and alcohol abuse and is exceedingly rare before the age of 30.  The median age is around 65 in both males and females.  It is located mostly in the middle and lower third of the esophagus.  Grossly, polypoid, ulcerated, plaque-like and occult lesions have been described.  The microscopic features are the same as in other squamous cell carcinomas.  Any degree of differentiation may occur, and variation within a single tumor is common.  The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Squamous Cell Carcinoma","conceptCode":"C4024","definition":"A squamous cell carcinoma arising from the esophagus.  It is associated with a long history of tobacco and alcohol abuse and is exceedingly rare before the age of 30.  The median age is around 65 in both males and females.  It is located mostly in the middle and lower third of the esophagus.  Grossly, polypoid, ulcerated, plaque-like and occult lesions have been described.  The microscopic features are the same as in other squamous cell carcinomas.  Any degree of differentiation may occur, and variation within a single tumor is common.  The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1DC4-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1DDD-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10017760","valueDescription":"Gastric Carcinoma","ValueMeaning":{"publicId":"3125028","version":"1","preferredName":"Gastric Carcinoma","longName":"3125028","preferredDefinition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Carcinoma","conceptCode":"C4911","definition":"A malignant epithelial tumor of the stomach mucosa. The vast majority of gastric carcinomas are adenocarcinomas, arising from the gastric glandular epithelium.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C8C84BA-75AC-B840-E040-BB89AD4308AA","latestVersionIndicator":"Yes","beginDate":"2010-07-29","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1DF1-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10030157","valueDescription":"Esophageal Carcinoma","ValueMeaning":{"publicId":"3210699","version":"1","preferredName":"Esophageal Carcinoma","longName":"3210699","preferredDefinition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Carcinoma","conceptCode":"C3513","definition":"A malignant epithelial tumor arising from the esophageal mucosa. Two major histologic types of esophageal carcinoma have been described: squamous cell carcinoma and adenocarcinoma. This type of cancer is associated with excessive ethanol and cigarette usage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9054-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1E05-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10001150","valueDescription":"Gastric Adenocarcinoma","ValueMeaning":{"publicId":"3206052","version":"1","preferredName":"Gastric Adenocarcinoma","longName":"3206052","preferredDefinition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals, most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Adenocarcinoma","conceptCode":"C4004","definition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals.  It most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F03F2AF-4F8F-0E9A-E040-BB89AD436762","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"BLABOLIJ","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1E1A-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10066354","valueDescription":"Adenocarcinoma of the Gastroesophageal Junction","ValueMeaning":{"publicId":"4722731","version":"1","preferredName":"Adenocarcinoma of the Gastroesophageal Junction","longName":"4722731","preferredDefinition":"An adenocarcinoma that arises from and straddles the junction of the stomach and esophagus.  The category of adenocarcinomas of the gastroesophageal junction also includes the majority of adenocarcinomas previously called gastric cardia adenocarcinomas.  Squamous cell carcinomas that affect or cross the junction of the stomach and esophagus are classified as carcinomas of the distal esophagus.  Adenocarcinoma of the gastroesophageal junction occurs more often in Caucasian middle aged and elderly males.  Clinical signs and symptoms include dysphagia, abdominal pain, and weight loss.  The prognosis depends on the completeness of the surgical resection, the number of lymph nodes involved by cancer, and the presence or absence of postoperative complications.  The presence of TP53 mutations indicates worse prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastroesophageal Junction Adenocarcinoma","conceptCode":"C9296","definition":"An adenocarcinoma that arises from and straddles the junction of the stomach and esophagus. The category of adenocarcinomas of the gastroesophageal junction also includes the majority of adenocarcinomas previously called gastric cardia adenocarcinomas. Squamous cell carcinomas that affect or cross the junction of the stomach and esophagus are classified as carcinomas of the distal esophagus. Adenocarcinoma of the gastroesophageal junction occurs more often in Caucasian middle aged and elderly males. Clinical signs and symptoms include dysphagia, abdominal pain, and weight loss. The prognosis depends on the completeness of the surgical resection, the number of lymph nodes involved by cancer, and the presence or absence of postoperative complications. The presence of TP53 mutations indicates worse prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1E27-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1E40-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10030139","valueDescription":"Esophageal Adenocarcinoma","ValueMeaning":{"publicId":"4722733","version":"1","preferredName":"Esophageal Adenocarcinoma","longName":"4722733","preferredDefinition":"A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophageal Adenocarcinoma","conceptCode":"C4025","definition":"A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus.  Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported.  Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas.  Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  The prognosis is poor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1E4D-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1E66-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10010029","valueDescription":"Colorectal Carcinoma","ValueMeaning":{"publicId":"4722734","version":"1","preferredName":"Colorectal Carcinoma","longName":"4722734","preferredDefinition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colorectal Carcinoma","conceptCode":"C2955","definition":"A malignant epithelial neoplasm that arises from the colon or rectum and invades through the muscularis mucosa into the submucosa.  The vast majority are adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1E70-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1E88-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10038045","valueDescription":"Rectal Adenocarcinoma","ValueMeaning":{"publicId":"3088062","version":"1","preferredName":"Rectal Adenocarcinoma","longName":"3088062","preferredDefinition":"An adenocarcinoma arising from the rectum.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, rectal adenocarcinomas are divided into well differentiated, moderately, and poorly differentiated.  Morphologic variants include the mucinous adenocarcinoma and signet-ring adenocarcinoma.  Lymphatic or hematogenous spread can occur early in the process and lead to systemic disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rectal Adenocarcinoma","conceptCode":"C9383","definition":"An adenocarcinoma arising from the rectum.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, rectal adenocarcinomas are divided into well, moderately, and poorly differentiated.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E18C0F-E245-9226-E040-BB89AD430EF0","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1E9D-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10009951","valueDescription":"Colon Adenocarcinoma","ValueMeaning":{"publicId":"3088065","version":"1","preferredName":"Colon Adenocarcinoma","longName":"3088065","preferredDefinition":"An adenocarcinoma arising from the colon.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, colonic adenocarcinomas are divided into well differentiated, moderately, and poorly differentiated.  Morphologic variants include the mucinous adenocarcinoma and signet-ring adenocarcinoma.  Lymphatic or hematogenous spread can occur early in the process and lead to systemic disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Colon Adenocarcinoma","conceptCode":"C4349","definition":"An adenocarcinoma arising from the colon.  It is more frequently seen in populations with a Western type diet and in patients with a history of chronic inflammatory bowel disease.  Signs and symptoms include intestinal bleeding, anemia, and change in bowel habits.  According to the degree of cellular differentiation, colonic adenocarcinomas are divided into well, moderately, and poorly differentiated.  Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E18C0F-E290-9226-E040-BB89AD430EF0","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-05-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1EB1-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10041840","valueDescription":"Anal Squamous Cell Carcinoma","ValueMeaning":{"publicId":"2580870","version":"1","preferredName":"Anal Squamous Cell Carcinoma","longName":"2580870","preferredDefinition":"A squamous cell carcinoma (SCC) arising in the anal canal or the anal margin (perianal skin).  The distinction between anal canal and anal margin SCC may be difficult, as tumors often involve both areas at the time of diagnosis.  The prognosis is generally better for anal margin SCC than for anal canal SCC.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anal Squamous Cell Carcinoma","conceptCode":"C9161","definition":"A squamous cell carcinoma (SCC) arising from the anal canal or the anal margin (perianal skin). Human papillomavirus is detected in the majority of cases. Homosexual HIV-positive men have an increased risk of developing anal squamous cell carcinoma in comparison to the general male population. Symptoms include anal pruritus, discomfort when sitting, pain, change in bowel habit, and bleeding. The prognosis is generally better for anal margin SCC than for anal canal SCC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-08F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-17","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-17","modifiedBy":"ONEDATA","dateModified":"2006-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1EC5-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10002126","valueDescription":"Anal Carcinoma","ValueMeaning":{"publicId":"4722735","version":"1","preferredName":"Anal Carcinoma","longName":"4722735","preferredDefinition":"A carcinoma that arises from the anus.  Anal carcinomas include the anal canal and anal margin (perianal skin) carcinomas.  The anal margin carcinoma is staged separately as a skin carcinoma.  Anal cancer stage terms are used as synonyms for anal canal cancer stage terms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anal Carcinoma","conceptCode":"C9291","definition":"A carcinoma that arises from the anus. Anal carcinomas include the anal canal and perianal area (anal margin) carcinomas. Perianal carcinomas are staged separately as skin carcinomas in AJCC v6 and v7 editions. The AJCC v8 edition staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1ED1-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1EEA-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10038918","valueDescription":"Retinoblastoma","ValueMeaning":{"publicId":"4265254","version":"1","preferredName":"Retinoblastoma","longName":"4265254","preferredDefinition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Retinoblastoma","conceptCode":"C7541","definition":"A malignant tumor that originates in the nuclear layer of the retina. As the most common primary tumor of the eye in children, retinoblastoma is still relatively uncommon, accounting for only 1% of all malignant tumors in pediatric patients. Approximately 95% of cases are diagnosed before age 5. These tumors may be multifocal, bilateral, congenital, inherited, or acquired. Seventy-five percent of retinoblastomas are unilateral; 60% occur sporadically. A predisposition to retinoblastoma has been associated with 13q14 cytogenetic abnormalities. Patients with the inherited form also appear to be at increased risk for secondary nonocular malignancies such as osteosarcoma, malignant fibrous histiocytoma, and fibrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4BEC-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1EFE-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025549","valueDescription":"Malignant Eye Neoplasm","ValueMeaning":{"publicId":"3210709","version":"1","preferredName":"Malignant Eye Neoplasm","longName":"3210709","preferredDefinition":"A primary or metastatic tumor involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal gland, and the orbit.  Representative examples are melanoma, carcinoma, lymphoma, and retinoblastoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Eye Neoplasm","conceptCode":"C4767","definition":"A primary or metastatic malignant neoplasm involving the structures of the eye (conjunctiva, cornea, uvea, retina), the lacrimal system, and the eyelid. Representative examples include melanoma, carcinoma, lymphoma, and retinoblastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9226-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1F13-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10043738","valueDescription":"Thyroid Gland Carcinoma","ValueMeaning":{"publicId":"2581280","version":"1","preferredName":"Thyroid Gland Carcinoma","longName":"2581280","preferredDefinition":"A carcinoma arising from the thyroid gland.  It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1F28-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033701","valueDescription":"Thyroid Gland Papillary Carcinoma","ValueMeaning":{"publicId":"4264948","version":"1","preferredName":"Thyroid Gland Papillary Carcinoma","longName":"4264948","preferredDefinition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  It is linked to radiation exposure and is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include: thyroid function tests, thyroid radioisotope scanning, thyroid ultrasound, and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.  Depending on the size and spread of the disease, surgical options include lobectomy, and partial or complete thyroidectomy.  Adjuvant treatment options include: radioiodine therapy, TSH suppression and external radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Papillary Carcinoma","conceptCode":"C4035","definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-38ED-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1F3C-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027105","valueDescription":"Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"2861420","version":"1","preferredName":"Thyroid Gland Medullary Carcinoma","longName":"2861420","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.  - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Medullary Carcinoma","conceptCode":"C3879","definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-5416-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1F51-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10016935","valueDescription":"Thyroid Gland Follicular Carcinoma","ValueMeaning":{"publicId":"3248467","version":"1","preferredName":"Thyroid Gland Follicular Carcinoma","longName":"3248467","preferredDefinition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  The nuclear features which characterise the thyroid gland papillary carcinoma are absent.  It is linked to radiation and comprises approximately 10% to 15% of thyroid cancers.  Clinically, it usually presents as a solitary mass in the thyroid gland.  It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels.  Diagnostic procedures include: thyroid function tests, thyroid radioisotope scanning, thyroid ultrasound and fine needle biopsy. Treatment options include: partial or complete thyroidectomy.  Adjuvant treatment options include: radioiodine therapy, TSH suppression and external radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Follicular Carcinoma","conceptCode":"C8054","definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  The nuclear features which characterize the thyroid gland papillary carcinoma are absent.  Radiation exposure is a risk factor and it comprises approximately 10% to 15% of thyroid cancers.  Clinically, it usually presents as a solitary mass in the thyroid gland.  It is generally unifocal and thickly encapsulated and shows invasion of the capsule or the vessels.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B722DF-A826-76E3-E040-BB89AD43333E","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1F8B-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10002240","valueDescription":"Thyroid Gland Undifferentiated (Anaplastic) Carcinoma","ValueMeaning":{"publicId":"4722738","version":"1","preferredName":"Thyroid Gland Undifferentiated (Anaplastic) Carcinoma","longName":"4722738","preferredDefinition":"A primary carcinoma of the thyroid gland composed of undifferentiated cells.  The malignant cells demonstrate evidence of epithelial differentiation, either by immunohistochemistry or electron microscopic studies. Microscopically, in the majority of cases there is a mixture of spindle, epithelioid, and giant cells. The vast majority of the patients present with a rapidly enlarging neck mass. The clinical course is usually aggressive.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Anaplastic Carcinoma","conceptCode":"C3878","definition":"A primary carcinoma of the thyroid gland composed of undifferentiated cells.  The malignant cells demonstrate evidence of epithelial differentiation, either by immunohistochemistry or electron microscopic studies. Microscopically, in the majority of cases there is a mixture of spindle, epithelioid, and giant cells. The vast majority of the patients present with a rapidly enlarging neck mass. The clinical course is usually aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1F95-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1FAE-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033965","valueDescription":"Parathyroid Gland Carcinoma","ValueMeaning":{"publicId":"3210719","version":"1","preferredName":"Parathyroid Gland Carcinoma","longName":"3210719","preferredDefinition":"A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Parathyroid Gland Carcinoma","conceptCode":"C4906","definition":"A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-93FA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1FC2-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10041056","valueDescription":"Pancreatic Small Cell Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2838839","version":"1","preferredName":"Pancreatic Small Cell Neuroendocrine Carcinoma","longName":"2838839","preferredDefinition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the presence of malignant small cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Small Cell Neuroendocrine Carcinoma","conceptCode":"C95583","definition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. It is characterized by the presence of malignant small cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9743A-23D9-8C94-E040-BB89AD4308C2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1FD7-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10034876","valueDescription":"Adrenal Gland Pheochromocytoma","ValueMeaning":{"publicId":"3210721","version":"1","preferredName":"Adrenal Gland Pheochromocytoma","longName":"3210721","preferredDefinition":"A benign or malignant neuroendocrine neoplasm of the sympathetic nervous system that secretes catecholamines.  It arises from the chromaffin cells of the adrenal medulla.  Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Gland Pheochromocytoma","conceptCode":"C3326","definition":"A neuroendocrine neoplasm of the sympathetic nervous system that arises from the chromaffin cells of the adrenal medulla and secretes catecholamines. Clinical presentation includes headaches, palpitations, chest and abdominal pain, hypertension, fever, and tremor.  Microscopically, a characteristic nesting (zellballen) growth pattern is usually seen.  Other growth patterns including trabecular pattern may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-943E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1FEB-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10057270","valueDescription":"Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2559503","version":"1","preferredName":"Neuroendocrine Carcinoma","longName":"2559503","preferredDefinition":"A malignant neuroendocrine tumor composed of cells containing secretory granules that stain positive for NSE and chromogranin.  Tumor cells are often round and form clusters or trabecular sheets.  Representative examples are carcinoid tumor, small cell carcinoma, and Merkel cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Carcinoma","conceptCode":"C3773","definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B57C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-1FFF-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10033630","valueDescription":"Pancreatic Neuroendocrine Tumor","ValueMeaning":{"publicId":"3250495","version":"1","preferredName":"Pancreatic Neuroendocrine Tumor","longName":"3250495","preferredDefinition":"A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Neuroendocrine Tumor","conceptCode":"C27720","definition":"A well differentiated, low, intermediate, or high grade neoplasm with neuroendocrine differentiation that arises from the pancreas.  According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6F215E6-C657-B293-E040-BB89AD432EF3","latestVersionIndicator":"Yes","beginDate":"2011-06-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2009-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10007276","valueDescription":"Carcinoid Tumor","ValueMeaning":{"publicId":"2956072","version":"1","preferredName":"Carcinoid Tumor","longName":"2956072","preferredDefinition":"Carcinoid tumor, also known as well differentiated endocrine neoplasm, is a slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoid Tumor","conceptCode":"C2915","definition":"A slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"76EBECE2-B719-A0E2-E040-BB89AD435984","latestVersionIndicator":"Yes","beginDate":"2009-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-201D-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10008907","valueDescription":"Chronic Graft Versus Host Disease","ValueMeaning":{"publicId":"2769010","version":"1","preferredName":"Chronic Graft Versus Host Disease","longName":"2769010","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Graft Versus Host Disease","conceptCode":"C4981","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, and may affect multiple organs with manifestations similar to autoimmune diseases. The onset is usually within three years of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53198A5F-9A9A-1FF8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"COOPERM","dateCreated":"2008-07-28","modifiedBy":"KUMMEROA","dateModified":"2023-10-30","changeDescription":null,"administrativeNotes":"2023.10.30 Alt VM added per ticket request CADSR0003010. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A8282-65D9-8ABC-E050-BB89AD43579F","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10002024","valueDescription":"Amyloidosis","ValueMeaning":{"publicId":"3210866","version":"1","preferredName":"Amyloidosis","longName":"3210866","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-ACBA-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A8282-65A2-8ABC-E050-BB89AD43579F","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10000802","valueDescription":"Acute Graft Versus Host Disease","ValueMeaning":{"publicId":"4722619","version":"1","preferredName":"Acute Graft Versus Host Disease","longName":"4722619v1.00","preferredDefinition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A8282-65AC-8ABC-E050-BB89AD43579F","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"KUMMEROA","dateModified":"2023-10-30","changeDescription":null,"administrativeNotes":"2023.10.30 Alt VM added per ticket request CADSR0003010. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A8282-65C5-8ABC-E050-BB89AD43579F","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10021425","valueDescription":"Immune System Disorder","ValueMeaning":{"publicId":"2578546","version":"1","preferredName":"Immune System Disorder","longName":"2578546","preferredDefinition":"A disorder resulting from an abnormality in the immune system. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune System Disorder","conceptCode":"C3507","definition":"A disorder resulting from an abnormality in the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FFDF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-05","modifiedBy":"ONEDATA","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A8282-65EE-8ABC-E050-BB89AD43579F","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10021510","valueDescription":"Immunodeficiency-Related Disorder","ValueMeaning":{"publicId":"4722621","version":"1","preferredName":"Immunodeficiency-Related Disorder","longName":"4722621","preferredDefinition":"A non-neoplastic or neoplastic disorder that develops in a patient with immunodeficiency. Representative examples include AIDS-related disorders and disorders that develop following organ transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunodeficiency-Related Disorder","conceptCode":"C35686","definition":"A non-neoplastic or neoplastic disorder that develops in a patient with immunodeficiency. Representative examples include AIDS-related disorders and disorders that develop following organ transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A8282-65FB-8ABC-E050-BB89AD43579F","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A8282-6614-8ABC-E050-BB89AD43579F","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90002028","valueDescription":"Lymphadenopathy with Polyclonal Hypergammaglobulinemia","ValueMeaning":{"publicId":"4722623","version":"1","preferredName":"Lymphadenopathy with Polyclonal Hypergammaglobulinemia","longName":"4722623","preferredDefinition":"A finding indicating the presence of enlarged lymph nodes and associated polyclonal hypergammaglobulinemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphadenopathy with Polyclonal Hypergammaglobulinemia","conceptCode":"C9307","definition":"A finding indicating the presence of enlarged lymph nodes and associated polyclonal hypergammaglobulinemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A8282-6621-8ABC-E050-BB89AD43579F","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A8282-663A-8ABC-E050-BB89AD43579F","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10035755","valueDescription":"Lymphocytic Interstitial Pneumonia","ValueMeaning":{"publicId":"4722625","version":"1","preferredName":"Lymphocytic Interstitial Pneumonia","longName":"4722625","preferredDefinition":"Interstitial pneumonia characterized by the presence of bibasilar pulmonary interstitial infiltrates composed of lymphocytes and plasma cells.  It may be associated with autoimmune and lymphoproliferative disorders.  Signs and symptoms include fever, cough, and dyspnea.  Symptomatic patients may require immunosuppressive treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocytic Interstitial Pneumonia","conceptCode":"C27558","definition":"Interstitial pneumonia characterized by the presence of bibasilar pulmonary interstitial infiltrates composed of lymphocytes and plasma cells.  It may be associated with autoimmune and lymphoproliferative disorders.  Signs and symptoms include fever, cough, and dyspnea.  Symptomatic patients may require immunosuppressive treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A8282-6647-8ABC-E050-BB89AD43579F","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A8282-6660-8ABC-E050-BB89AD43579F","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10046890","valueDescription":"Vaginal Intraepithelial Neoplasia","ValueMeaning":{"publicId":"3252118","version":"1","preferredName":"Vaginal Intraepithelial Neoplasia","longName":"3252118","preferredDefinition":"A superficial neoplastic process involving exclusively the vaginal squamous epithelium without extension to underlying tissue.  It is classified as low- or high-grade intraepithelial neoplasia.  --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaginal Intraepithelial Neoplasia","conceptCode":"C4521","definition":"A superficial neoplastic process involving exclusively the vaginal squamous epithelium without extension to underlying tissue.  It is classified as low- or high-grade intraepithelial neoplasia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A781D14A-E6AC-8A44-E040-BB89AD4310FD","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1008A07F-0053-71C6-E050-BB89AD4343A8","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-26","modifiedBy":"ONEDATA","dateModified":"2015-02-26","deletedIndicator":"No"},{"value":"10065861","valueDescription":"Thyroid Gland Oncocytic Neoplasm","ValueMeaning":{"publicId":"4722737","version":"1","preferredName":"Thyroid Gland Oncocytic Neoplasm","longName":"4722737","preferredDefinition":"An adenoma or carcinoma arising from the follicular cells of the thyroid gland.  It is composed of large oncocytic cells with abundant granular eosinophilic cytoplasm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Oncocytic Neoplasm","conceptCode":"C46068","definition":"An adenoma or carcinoma arising from the follicular cells of the thyroid gland.  It is composed of large oncocytic cells with abundant granular eosinophilic cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-1F5E-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1008A07F-0067-71C6-E050-BB89AD4343A8","beginDate":"2015-02-20","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-26","modifiedBy":"ONEDATA","dateModified":"2015-02-26","deletedIndicator":"No"},{"value":"10014709","valueDescription":"Malignant Endocrine Neoplasm","ValueMeaning":{"publicId":"4722740","version":"1","preferredName":"Malignant Endocrine Neoplasm","longName":"4722740","preferredDefinition":"A malignant neoplasm affecting the endocrine glands.  Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Endocrine Neoplasm","conceptCode":"C3575","definition":"A malignant neoplasm affecting the endocrine glands.  Representative examples include thyroid gland carcinoma, parathyroid gland carcinoma, pituitary gland carcinoma, and adrenal cortex carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-202A-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2043-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10001327","valueDescription":"Adrenal Cortex Carcinoma","ValueMeaning":{"publicId":"3248212","version":"1","preferredName":"Adrenal Cortex Carcinoma","longName":"3248212","preferredDefinition":"A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Cortical Carcinoma","conceptCode":"C9325","definition":"A rare, usually large (greater than 5cm), malignant epithelial tumor arising from the adrenal cortical cells.  Symptoms are usually related to the excessive production of hormones, and include Cushing's syndrome and virilism in women.  Common sites of metastasis include liver, lung, bone, and retroperitoneal lymph nodes.  Advanced radiologic procedures have enabled the detection of small tumors, resulting in the improvement of the 5-year survival.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B537E2-7FB8-5E57-E040-BB89AD4339B4","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2057-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029268","valueDescription":"Neurofibromatosis","ValueMeaning":{"publicId":"2568792","version":"1","preferredName":"Neurofibromatosis","longName":"2568792","preferredDefinition":"A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibromatosis","conceptCode":"C6727","definition":"An autosomal dominant hereditary neoplastic syndrome. Two distinct clinicopathological entities are recognized: neurofibromatosis type 1 and neurofibromatosis type 2. Neurofibromatosis type 1 is associated with the presence of cafe-au-lait cutaneous lesions, multiple neurofibromas, malignant peripheral nerve sheath tumors, optic nerve gliomas, and bone lesions. Neurofibromatosis type 2 is associated with the presence of schwannomas, meningiomas, and gliomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D9C5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-29","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2061-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029261","valueDescription":"Neuroblastoma","ValueMeaning":{"publicId":"4265259","version":"1","preferredName":"Neuroblastoma","longName":"4265259","preferredDefinition":"A neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4CCE-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2075-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029208","valueDescription":"Peripheral Nervous System Neoplasm","ValueMeaning":{"publicId":"3210720","version":"1","preferredName":"Peripheral Nervous System Neoplasm","longName":"3210720","preferredDefinition":"A benign or malignant neoplasm arising from a peripheral nerve or the perineural sheaths.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral Nervous System Neoplasm","conceptCode":"C3321","definition":"A benign or malignant neoplasm arising from a peripheral nerve or the perineural sheaths.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-941C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-208A-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10035106","valueDescription":"Pituitary Gland Carcinoma","ValueMeaning":{"publicId":"4722742","version":"1","preferredName":"Pituitary Gland Carcinoma","longName":"4722742","preferredDefinition":"A rare adenocarcinoma with poor prognosis, arising from the adenohypophysial cells of the anterior lobe of the pituitary gland or pre-existing adenomas.  The majority are hormonally functioning neoplasms, usually producing prolactin or ACTH.  The diagnosis is based on the presence of metastases.  Syndromes associated with pituitary gland carcinomas include hyperprolactinemia, Cushing disease, and acromegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic Pituitary Neuroendocrine Tumor","conceptCode":"C4536","definition":"Pituitary neuroendocrine tumor that has spread from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-2098-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-20B1-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10011318","valueDescription":"Craniopharyngioma","ValueMeaning":{"publicId":"4265243","version":"1","preferredName":"Craniopharyngioma","longName":"4265243","preferredDefinition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Craniopharyngioma","conceptCode":"C2964","definition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-794B-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-20BB-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10028537","valueDescription":"Primary Myelofibrosis","ValueMeaning":{"publicId":"4130282","version":"1","preferredName":"Primary Myelofibrosis","longName":"4130282","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis.  The cause is unknown.  The median survival time is 3-5 years from diagnosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F18569AC-01B0-4E6D-E040-BB89AD437CF4","latestVersionIndicator":"Yes","beginDate":"2014-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-20D0-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10009013","valueDescription":"Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"4722771","version":"1","preferredName":"Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia","longName":"4722771","preferredDefinition":"A chronic myelogenous leukemia characterised by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive","conceptCode":"C9128","definition":"A chronic myeloid leukemia characterised by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-20DB-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-20F4-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10015493","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2108-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10036061","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2838666","version":"1","preferredName":"Polycythemia Vera","longName":"2838666","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-960E-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-211C-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10024312","valueDescription":"Leukemia","ValueMeaning":{"publicId":"3179697","version":"1","preferredName":"Leukemia","longName":"3179697","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F258D4-9F60-3E56-E040-BB89AD436715","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2130-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10028534","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"3946618","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"3946618","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA87B0E5-6712-6876-E040-BB89AD437204","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-06","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2145-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10009018","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2159-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10023249","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2838584","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2838584","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5942-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-216D-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025325","valueDescription":"Lymphomatoid Granulomatosis","ValueMeaning":{"publicId":"2838594","version":"1","preferredName":"Lymphomatoid Granulomatosis","longName":"2838594","preferredDefinition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Granulomatosis","conceptCode":"C7930","definition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F7F1-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2182-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10020231","valueDescription":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","ValueMeaning":{"publicId":"2838645","version":"1","preferredName":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","longName":"2838645","preferredDefinition":"A monoclonal B-cell neoplasm characterized by a nodular, or a nodular and diffuse, polymorphous proliferation of scattered large neoplastic cells known as popcorn or L&H cells; the L&H cells are CD15 negative, and rarely positive for CD30 antigen.  Patients are predominantly male, frequently in the 30-50 year age group.  Most patients present with limited stage disease (localized peripheral lymphadenopathy, stage I or II); the prognosis of patients with stage I and stage II disease is very good.  Advanced stages have an unfavorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","conceptCode":"C7258","definition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9584-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"DWARZEL","dateModified":"2012-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2196-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10020255","valueDescription":"Hodgkin Lymphoma","ValueMeaning":{"publicId":"2573074","version":"1","preferredName":"Hodgkin Lymphoma","longName":"2573074","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of large tumor cells in an abundant admixture of nonneoplastic cells. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA7F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"TAYLORT","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-21A1-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600328","valueDescription":"Hodgkin-Like Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"4722773","version":"1","preferredName":"Hodgkin-Like Post-Transplant Lymphoproliferative Disorder","longName":"4722773","preferredDefinition":"A lymphoproliferative disorder with morphologic features resembling Hodgkin lymphoma that develops in a patient following transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin-Like Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7239","definition":"A lymphoproliferative disorder with morphologic features resembling Hodgkin lymphoma that develops in a patient following transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-21AE-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-21C7-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025316","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"2567355","version":"1","preferredName":"Lymphoma","longName":"2567355","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D428-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-21DB-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065863","valueDescription":"Primary Cutaneous Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"2838708","version":"1","preferredName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","longName":"2838708","preferredDefinition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","conceptCode":"C6860","definition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-971A-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-21EF-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065864","valueDescription":"Systemic Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"3322391","version":"1","preferredName":"Systemic Anaplastic Large Cell Lymphoma","longName":"3322391","preferredDefinition":"An anaplastic large cell lymphoma that is not confined to a single anatomic site and involves multiple nodal and/or extranodal sites.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Anaplastic Large Cell Lymphoma","conceptCode":"C9470","definition":"An anaplastic large cell lymphoma that is not confined to a single anatomic site and involves multiple nodal and/or extranodal sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BC9E-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2204-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065872","valueDescription":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","ValueMeaning":{"publicId":"4130283","version":"1","preferredName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","longName":"4130283","preferredDefinition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","conceptCode":"C4563","definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F18569AC-01D3-4E6D-E040-BB89AD437CF4","latestVersionIndicator":"Yes","beginDate":"2014-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-223F-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065862","valueDescription":"T-Cell Large Granular Lymphocyte Leukemia","ValueMeaning":{"publicId":"2590775","version":"1","preferredName":"T-Cell Large Granular Lymphocyte Leukemia","longName":"2590775","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F6CF08-5979-36DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2254-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10036888","valueDescription":"Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2590867","version":"1","preferredName":"Prolymphocytic Leukemia","longName":"2590867","preferredDefinition":"PLL. A type of chronic lymphocyctic leukemia (CLL), in which too many immature white blood cells (prolymphocytes) are found in the blood and bone marrow. PLL usually progresses more rapidly than classic CLL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prolymphocytic Leukemia","conceptCode":"C3181","definition":"A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2843C971-29F3-37A6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2268-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10019053","valueDescription":"Hairy Cell Leukemia","ValueMeaning":{"publicId":"2838575","version":"1","preferredName":"Hairy Cell Leukemia","longName":"2838575","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5837-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-227C-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10008960","valueDescription":"Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"4264837","version":"1","preferredName":"Chronic Lymphocytic Leukemia","longName":"4264837","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FFD5-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2290-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10001415","valueDescription":"Adult T-Cell Leukemia/Lymphoma","ValueMeaning":{"publicId":"4264852","version":"1","preferredName":"Adult T-Cell Leukemia/Lymphoma","longName":"4264852","preferredDefinition":"A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-025B-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-22A5-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10066353","valueDescription":"Therapy-Related Acute Myeloid Leukemia","ValueMeaning":{"publicId":"3251312","version":"1","preferredName":"Therapy-Related Acute Myeloid Leukemia","longName":"3251312","preferredDefinition":"An acute myeloid leukemia arising as a result of the mutagenic effect of alkylating agents and/or ionizing radiation.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","conceptCode":"C8252","definition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A757E577-0AFA-B648-E040-BB89AD434049","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-22BA-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10001019","valueDescription":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","ValueMeaning":{"publicId":"4722782","version":"1","preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","longName":"4722782","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C3182","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-22C4-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-22DD-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10054569","valueDescription":"T Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263973","version":"1","preferredName":"T Acute Lymphoblastic Leukemia","longName":"4263973","preferredDefinition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1133-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2314-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10003890","valueDescription":"B Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263974","version":"1","preferredName":"B Acute Lymphoblastic Leukemia","longName":"4263974","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1156-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2329-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10000846","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2334-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025638","valueDescription":"Systemic Mastocytosis","ValueMeaning":{"publicId":"3211467","version":"1","preferredName":"Systemic Mastocytosis","longName":"3211467","preferredDefinition":"A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Mastocytosis","conceptCode":"C9235","definition":"Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-022B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2348-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025581","valueDescription":"Langerhans Cell Histiocytosis","ValueMeaning":{"publicId":"2559022","version":"1","preferredName":"Langerhans Cell Histiocytosis","longName":"2559022","preferredDefinition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination.  Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease.  The clinical course is generally related to the number of organs affected at presentation.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Histiocytosis","conceptCode":"C3107","definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B39B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-235D-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10018864","valueDescription":"Hematopoietic and Lymphoid Cell Neoplasm","ValueMeaning":{"publicId":"4265238","version":"1","preferredName":"Hematopoietic and Lymphoid Cell Neoplasm","longName":"4265238","preferredDefinition":"A cancer of the blood or bone marrow, such as leukemia or lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic and Lymphoid Cell Neoplasm","conceptCode":"C27134","definition":"A neoplasm that arises from hematopoietic and lymphoid cells. Representative examples include myeloproliferative neoplasms, myelodysplastic syndromes, leukemias, Hodgkin lymphomas, and non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-7851-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"TSESU","dateModified":"2023-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2371-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10039397","valueDescription":"Malignant Salivary Gland Neoplasm","ValueMeaning":{"publicId":"4722785","version":"1","preferredName":"Malignant Salivary Gland Neoplasm","longName":"4722785","preferredDefinition":"A primary or metastatic malignant neoplasm that affects the major or minor salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Salivary Gland Neoplasm","conceptCode":"C3811","definition":"A primary or metastatic malignant neoplasm that affects the major or minor salivary glands.  Representative examples include carcinoma, lymphoma, and sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-237F-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-2398-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10028786","valueDescription":"Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"4264956","version":"1","preferredName":"Nasopharyngeal Carcinoma","longName":"4264956","preferredDefinition":"A carcinoma arising from the nasopharyngeal epithelium.  It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasopharyngeal Carcinoma","conceptCode":"C3871","definition":"A carcinoma arising from the nasopharyngeal epithelium.  It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3A91-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-23AC-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10034819","valueDescription":"Pharyngeal Squamous Cell Carcinoma","ValueMeaning":{"publicId":"3794702","version":"1","preferredName":"Pharyngeal Squamous Cell Carcinoma","longName":"3794702","preferredDefinition":"A squamous cell carcinoma that arises from the pharynx.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharyngeal Squamous Cell Carcinoma","conceptCode":"C102872","definition":"A squamous cell carcinoma that arises from the pharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E010110A-EA36-64DE-E040-BB89AD431324","latestVersionIndicator":"Yes","beginDate":"2013-06-26","endDate":null,"createdBy":"SHIDED","dateCreated":"2013-06-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8A7B21-23C1-7895-E050-BB89AD43579D","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10023290","valueDescription":"AIDS-Related Kaposi Sarcoma","ValueMeaning":{"publicId":"4722339","version":"1","preferredName":"AIDS-Related Kaposi Sarcoma","longName":"4722339","preferredDefinition":"The most aggressive form of Kaposi sarcoma. It presents in patients who are infected with the human immunodeficiency virus. It can affect the skin and internal organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Kaposi Sarcoma","conceptCode":"C3992","definition":"The most aggressive form of Kaposi sarcoma. It presents in patients who are infected with the human immunodeficiency virus. It can affect the skin and internal organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F78C75D-7C54-2AC1-E050-BB89AD437AC5","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F78C75D-7C6D-2AC1-E050-BB89AD437AC5","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"ONEDATA","dateModified":"2015-02-19","deletedIndicator":"No"},{"value":"90600068","valueDescription":"Human Papillomavirus-Related Malignant Neoplasm in AIDS Patient","ValueMeaning":{"publicId":"4722341","version":"1","preferredName":"Human Papillomavirus-Related Malignant Neoplasm in AIDS Patient","longName":"4722341","preferredDefinition":"A malignant neoplasm caused by human papillomavirus in an a patient with a history of AIDS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Papillomavirus-Related Malignant Neoplasm in AIDS Patient","conceptCode":"C102884","definition":"A malignant neoplasm caused by human papillomavirus in an a patient with a history of AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F78C75D-7C7A-2AC1-E050-BB89AD437AC5","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F78C75D-7C93-2AC1-E050-BB89AD437AC5","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"ONEDATA","dateModified":"2015-02-19","deletedIndicator":"No"},{"value":"10063001","valueDescription":"AIDS-Related Human Papillomavirus Infection","ValueMeaning":{"publicId":"4722343","version":"1","preferredName":"AIDS-Related Human Papillomavirus Infection","longName":"4722343","preferredDefinition":"An opportunistic infection caused by the human papillomavirus in a patient with AIDS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Human Papillomavirus Infection","conceptCode":"C103296","definition":"An opportunistic infection caused by the human papillomavirus in a patient with AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F78C75D-7CA0-2AC1-E050-BB89AD437AC5","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F78C75D-7CB9-2AC1-E050-BB89AD437AC5","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"ONEDATA","dateModified":"2015-02-19","deletedIndicator":"No"},{"value":"10008229","valueDescription":"AIDS-Related Cervical Carcinoma","ValueMeaning":{"publicId":"4722345","version":"1","preferredName":"AIDS-Related Cervical Carcinoma","longName":"4722345","preferredDefinition":"A carcinoma that arises from the cervix in a patient with acquired immunodeficiency syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Cervical Carcinoma","conceptCode":"C7432","definition":"A carcinoma that arises from the cervix in a patient with acquired immunodeficiency syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F78C75D-7CC6-2AC1-E050-BB89AD437AC5","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F78C75D-7CDF-2AC1-E050-BB89AD437AC5","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"ONEDATA","dateModified":"2015-02-19","deletedIndicator":"No"},{"value":"10065860","valueDescription":"AIDS-Related Anal Carcinoma","ValueMeaning":{"publicId":"4722347","version":"1","preferredName":"AIDS-Related Anal Carcinoma","longName":"4722347","preferredDefinition":"A carcinoma arising from the anus and occurring in HIV-positive patients. Homosexual HIV-positive men have an increased risk of developing anal squamous cell carcinoma in comparison to the general male population. Sexually transmitted human papillomavirus is detected in the majority of the cases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Anal Carcinoma","conceptCode":"C9278","definition":"A carcinoma arising from the anus and occurring in HIV-positive patients. Homosexual HIV-positive men have an increased risk of developing anal squamous cell carcinoma in comparison to the general male population. Sexually transmitted human papillomavirus is detected in the majority of the cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F78C75D-7CEC-2AC1-E050-BB89AD437AC5","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F78C75D-7D05-2AC1-E050-BB89AD437AC5","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"ONEDATA","dateModified":"2015-02-19","deletedIndicator":"No"},{"value":"10031291","valueDescription":"Osteosarcoma","ValueMeaning":{"publicId":"3179363","version":"1","preferredName":"Osteosarcoma","longName":"3179363","preferredDefinition":"A usually aggressive malignant bone-forming mesenchymal tumor, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteosarcoma","conceptCode":"C9145","definition":"A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-8659-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"REEVESD","dateModified":"2014-07-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F870C21-CFB3-A2CF-E050-BB89AD435BE0","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10015563","valueDescription":"Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","ValueMeaning":{"publicId":"4265241","version":"1","preferredName":"Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","longName":"4265241","preferredDefinition":"Round cell sarcomas with varying degrees of neuroectodermal differentiation.  There is a recurrent cytogenetic aberration, most commonly t(11;22)(q24;q12) and t(21;22)(q22;q12).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","conceptCode":"C27291","definition":"A spectrum of malignant tumors, affecting mostly males under age 20, characterized morphologically by the presence of small round cells.  Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor.  Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities.  These tumors may occur in the soft tissues or the bones.  Pain and the presence of a mass are the most common clinical symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68C00B1-78E4-6438-E040-BB89AD4373BF","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F870C21-CFC7-A2CF-E050-BB89AD435BE0","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10008737","valueDescription":"Chondrosarcoma","ValueMeaning":{"publicId":"3179236","version":"1","preferredName":"Chondrosarcoma","longName":"3179236","preferredDefinition":"A malignant mesenchymal tumor arising from cartilage-forming tissues involving the bones.  It affects middle-aged to elderly adults, and the pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondrosarcoma","conceptCode":"C2946","definition":"A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue.  It usually affects middle-aged to elderly adults.  The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement.  Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9881C41C-CDA1-C63B-E040-BB89AD437873","latestVersionIndicator":"Yes","beginDate":"2010-12-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-28","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F870C21-CFDC-A2CF-E050-BB89AD435BE0","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10020188","valueDescription":"HIV Positivity","ValueMeaning":{"publicId":"4722472","version":"1","preferredName":"HIV Positivity","longName":"4722472","preferredDefinition":"A laboratory test result indicating the presence of the human immunodeficiency virus (HIV) in a sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Immunodeficiency Virus Positive","conceptCode":"C15175","definition":"A laboratory test result indicating the presence of the human immunodeficiency virus (HIV) in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F870C21-CFE9-A2CF-E050-BB89AD435BE0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F870C21-D002-A2CF-E050-BB89AD435BE0","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025280","valueDescription":"Diffuse Infiltrative Lymphocytosis Syndrome","ValueMeaning":{"publicId":"4722474","version":"1","preferredName":"Diffuse Infiltrative Lymphocytosis Syndrome","longName":"4722474","preferredDefinition":"This is usually an oligoclonal CD8+ lymphocytic infiltration of various organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Infiltrative Lymphocytosis Syndrome","conceptCode":"C35699","definition":"This is usually an oligoclonal CD8+ lymphocytic infiltration of various organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F870C21-D00F-A2CF-E050-BB89AD435BE0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F870C21-D028-A2CF-E050-BB89AD435BE0","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10049026","valueDescription":"AIDS-Related Disorder","ValueMeaning":{"publicId":"3210811","version":"1","preferredName":"AIDS-Related Disorder","longName":"3210811","preferredDefinition":"A non-neoplastic or neoplastic disorder arising as a result of the immunologic defects caused by Autoimmune Deficiency Syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Disorder","conceptCode":"C4991","definition":"A non-neoplastic or neoplastic disorder arising as a result of the immunologic defects caused by Autoimmune Deficiency Syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A3E4-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F870C21-D03C-A2CF-E050-BB89AD435BE0","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600080","valueDescription":"AIDS-Related Primary Central Nervous System Lymphoma","ValueMeaning":{"publicId":"4722476","version":"1","preferredName":"AIDS-Related Primary Central Nervous System Lymphoma","longName":"4722476","preferredDefinition":"A lymphoma (non-Hodgkin or Hodgkin) arising from the central nervous system and occurring in HIV-positive patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Primary Central Nervous System Lymphoma","conceptCode":"C8284","definition":"A lymphoma (non-Hodgkin or Hodgkin) arising from the central nervous system and occurring in HIV-positive patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F870C21-D04A-A2CF-E050-BB89AD435BE0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F870C21-D063-A2CF-E050-BB89AD435BE0","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600308","valueDescription":"AIDS-Related Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"4722457","version":"1","preferredName":"AIDS-Related Non-Hodgkin Lymphoma","longName":"4722457","preferredDefinition":"A non-Hodgkin lymphoma that develops in a patient with AIDS.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Non-Hodgkin Lymphoma","conceptCode":"C5051","definition":"A non-Hodgkin lymphoma that develops in a patient with AIDS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F86183D-E154-2456-E050-BB89AD4355BA","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F86183D-E16D-2456-E050-BB89AD4355BA","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"90600076","valueDescription":"AIDS-Related Hodgkin Lymphoma","ValueMeaning":{"publicId":"4722459","version":"1","preferredName":"AIDS-Related Hodgkin Lymphoma","longName":"4722459","preferredDefinition":"Hodgkin lymphoma secondary to AIDS. An increased incidence of Hodgkin lymphomas has been observed in HIV positive patients. Most cases are morphologically classified as lymphocyte depleted or mixed cellularity Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Hodgkin Lymphoma","conceptCode":"C9279","definition":"Hodgkin lymphoma secondary to AIDS. An increased incidence of Hodgkin lymphomas has been observed in HIV positive patients. Most cases are morphologically classified as lymphocyte depleted or mixed cellularity Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F86183D-E17A-2456-E050-BB89AD4355BA","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F86183D-E193-2456-E050-BB89AD4355BA","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10030286","valueDescription":"Oligodendroglioma","ValueMeaning":{"publicId":"2838655","version":"1","preferredName":"Oligodendroglioma","longName":"2838655","preferredDefinition":"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A770F5-59CD-03F5-E040-BB89AD435AD2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F899F68-B6CE-D077-E050-BB89AD434EE9","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027189","valueDescription":"Meningioma","ValueMeaning":{"publicId":"4265263","version":"1","preferredName":"Meningioma","longName":"4265263","preferredDefinition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4D52-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F899F68-B6E2-D077-E050-BB89AD434EE9","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065853","valueDescription":"Nongerminomatous Germ Cell Tumor","ValueMeaning":{"publicId":"4722573","version":"1","preferredName":"Nongerminomatous Germ Cell Tumor","longName":"4722573","preferredDefinition":"Germ cell tumors of the central nervous system other than germinoma.  This category includes teratoma, choriocarcinoma, embryonal carcinoma, and yolk sac tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Nongerminomatous Germ Cell Tumor","conceptCode":"C100093","definition":"Germ cell tumors of the central nervous system other than germinoma.  This category includes teratoma, choriocarcinoma, embryonal carcinoma, and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F899F68-B6F0-D077-E050-BB89AD434EE9","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F899F68-B709-D077-E050-BB89AD434EE9","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065852","valueDescription":"Central Nervous System Germinoma","ValueMeaning":{"publicId":"4722577","version":"1","preferredName":"Central Nervous System Germinoma","longName":"4722577","preferredDefinition":"A malignant germ cell tumor arising from the central nervous system.  It is composed of uniform cells resembling primitive germ cells.  These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm.  Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells.  (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Germinoma","conceptCode":"C7009","definition":"A malignant germ cell tumor arising from the central nervous system.  It is composed of uniform cells resembling primitive germ cells.  These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm.  Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells.  (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F899F68-B716-D077-E050-BB89AD434EE9","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F899F68-B72F-D077-E050-BB89AD434EE9","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10014967","valueDescription":"Ependymoma","ValueMeaning":{"publicId":"2578706","version":"1","preferredName":"Ependymoma","longName":"2578706","preferredDefinition":"Ependymoma (WHO grade II) is the most common ependymal neoplasm. It is a slow growing tumor of children and young adults and is usually located intraventricularly.  It often causes clinical symptoms by blocking CSF pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes.(Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F899F68-B743-D077-E050-BB89AD434EE9","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10056672","valueDescription":"Supratentorial primitive neuroectodermal tumor","ValueMeaning":{"publicId":"2578697","version":"1","preferredName":"Supratentorial primitive neuroectodermal tumor","longName":"2578697","preferredDefinition":"A primitive and aggressive malignant neoplasm, usually arising from the cerebral hemispheres.  It is characterized by the presence of poorly differentiated or undifferentiated neuroepithelial cells.  This category includes tumors with exclusively neuronal differentiation which are termed cerebral neuroblastomas and tumors which contain ganglion cells and are termed ganglioneuroblastomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Supratentorial Embryonal Tumor, Not Otherwise Specified","conceptCode":"C6968","definition":"A central nervous system embryonal tumor, not otherwise specified arising from the supratentorial region.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0076-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F899F68-B74D-D077-E050-BB89AD434EE9","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10027107","valueDescription":"Medulloblastoma","ValueMeaning":{"publicId":"4265264","version":"1","preferredName":"Medulloblastoma","longName":"4265264","preferredDefinition":"A malignant, invasive embryonal neoplasm arising from the cerebellum. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, large cell medulloblastoma, and medulloblastoma with extensive nodularity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma","conceptCode":"C3222","definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4D75-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F899F68-B757-D077-E050-BB89AD434EE9","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10039024","valueDescription":"Rhabdomyosarcoma","ValueMeaning":{"publicId":"4265253","version":"1","preferredName":"Rhabdomyosarcoma","longName":"4265253","preferredDefinition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomical sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdomyosarcoma","conceptCode":"C3359","definition":"A rare aggressive malignant mesenchymal neoplasm arising from skeletal muscle. It usually occurs in children and young adults. Only a small percentage of tumors arise in the skeletal muscle of the extremities. The majority arise in other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4BB4-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8748A7-4706-DF2B-E050-BB89AD4311E0","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10061271","valueDescription":"Soft Tissue Neoplasm","ValueMeaning":{"publicId":"4722494","version":"1","preferredName":"Soft Tissue Neoplasm","longName":"4722494","preferredDefinition":"A benign or malignant neoplasm that arises from mesenchymal cells in extra skeletal sites.  The most common types are lipomatous (fatty), vascular, smooth muscle, fibrous, and fibrohistiocytic neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Neoplasm","conceptCode":"C3377","definition":"A benign, intermediate, or malignant neoplasm that arises from the soft tissue.  The most common types are lipomatous (fatty), vascular, smooth muscle, fibrous, and fibrohistiocytic neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8748A7-4713-DF2B-E050-BB89AD4311E0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8748A7-472C-DF2B-E050-BB89AD4311E0","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10044409","valueDescription":"Urothelial Carcinoma","ValueMeaning":{"publicId":"3155848","version":"1","preferredName":"Urothelial Carcinoma","longName":"3155848","preferredDefinition":"A malignant neoplasm derived from the transitional epithelium of the urinary tract (urinary bladder, ureter, urethra, or renal pelvis).  It is frequently papillary. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urothelial Carcinoma","conceptCode":"C4030","definition":"A carcinoma arising from the urothelial lining of the urinary tract (bladder, renal pelvis, ureter, or urethra).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"943B8AF5-84AC-8068-E040-BB89AD437602","latestVersionIndicator":"Yes","beginDate":"2010-11-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8748A7-4740-DF2B-E050-BB89AD4311E0","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10018192","valueDescription":"Malignant Urinary System Neoplasm","ValueMeaning":{"publicId":"4722496","version":"1","preferredName":"Malignant Urinary System Neoplasm","longName":"4722496","preferredDefinition":"A primary or metastatic malignant tumor involving the urinary system.  Common tumor types include carcinomas, lymphomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Urinary System Neoplasm","conceptCode":"C9297","definition":"A primary or metastatic malignant neoplasm involving the urinary system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8748A7-474D-DF2B-E050-BB89AD4311E0","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8748A7-4766-DF2B-E050-BB89AD4311E0","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10025556","valueDescription":"Unclassified Pleomorphic Sarcoma","ValueMeaning":{"publicId":"4417403","version":"1","preferredName":"Unclassified Pleomorphic Sarcoma","longName":"4417403","preferredDefinition":"A pleomorphic sarcoma characterized by the presence of fibrohistiocytic cells and spindle cells arranged in a storiform pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Pleomorphic Sarcoma","conceptCode":"C4247","definition":"An undifferentiated soft tissue sarcoma characterized by the presence of a pleomorphic malignant cellular infiltrate.  It is also known as malignant fibrous histiocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF69122E-9D72-60EF-E040-BB89AD436B90","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8748A7-47BB-DF2B-E050-BB89AD4311E0","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10026667","valueDescription":"Malignant Peripheral Nerve Sheath Tumor","ValueMeaning":{"publicId":"2838605","version":"1","preferredName":"Malignant Peripheral Nerve Sheath Tumor","longName":"2838605","preferredDefinition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peripheral Nerve Sheath Tumor","conceptCode":"C3798","definition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE88-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8748A7-47D0-DF2B-E050-BB89AD4311E0","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065866","valueDescription":"Plexiform Neurofibroma","ValueMeaning":{"publicId":"2838639","version":"1","preferredName":"Plexiform Neurofibroma","longName":"2838639","preferredDefinition":"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plexiform Neurofibroma","conceptCode":"C3797","definition":"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5A5E-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8748A7-47F8-DF2B-E050-BB89AD4311E0","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10024631","valueDescription":"Liposarcoma","ValueMeaning":{"publicId":"3179354","version":"1","preferredName":"Liposarcoma","longName":"3179354","preferredDefinition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Representative morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid/round cell liposarcoma.  The metastatic potential is higher in less differentiated tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liposarcoma","conceptCode":"C3194","definition":"A usually painless malignant tumor that arises from adipose tissue.  Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes.  Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma.  The metastatic potential is higher in less differentiated tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-84F7-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F883844-381E-1A54-E050-BB89AD4360C3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10004146","valueDescription":"Skin Basal Cell Carcinoma","ValueMeaning":{"publicId":"2961462","version":"1","preferredName":"Skin Basal Cell Carcinoma","longName":"2961462","preferredDefinition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Basal Cell Carcinoma","conceptCode":"C2921","definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B5C7-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F883844-3881-1A54-E050-BB89AD4360C3","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10034624","valueDescription":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"4173735","version":"1","preferredName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","longName":"4173735","preferredDefinition":"Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas.  This category includes the following variants: lymphoepithelioid cell variant (Lennert's lymphoma), follicular variant, and T-zone variant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C4340","definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D84E5-7AD8-4906-E040-BB89AD434E8B","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C2F7-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10036525","valueDescription":"B Lymphoblastic Lymphoma","ValueMeaning":{"publicId":"4722715","version":"1","preferredName":"B Lymphoblastic Lymphoma","longName":"4722715","preferredDefinition":"An uncommon type of lymphoma.  It constitutes approximately 10% of cases of lymphoblastic lymphoma.  Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age.  The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes.  It has a high remission rate with a median survival of approximately 60 months.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Lymphoma","conceptCode":"C8868","definition":"An uncommon type of lymphoma.  It constitutes approximately 10% of cases of lymphoblastic lymphoma.  Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age.  The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes.  It has a high remission rate with a median survival of approximately 60 months.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C32A-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C343-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10036545","valueDescription":"T Lymphoblastic Lymphoma","ValueMeaning":{"publicId":"3251335","version":"1","preferredName":"T Lymphoblastic Lymphoma","longName":"3251335","preferredDefinition":"The most frequent type of lymphoblastic lymphoma.  It comprises approximately 85-90% of cases.  It is more frequently seen in adolescent males.  It frequently presents with a mass lesion in the mediastinum.  Pleural effusions are common.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Lymphoblastic Lymphoma","conceptCode":"C6919","definition":"The most frequent type of lymphoblastic lymphoma.  It comprises approximately 85-90% of cases.  It is more frequently seen in adolescent males.  It frequently presents with a mass lesion in the mediastinum.  Pleural effusions are common.  (WHO, 2001)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9D09-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C357-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065857","valueDescription":"Primary Effusion Lymphoma","ValueMeaning":{"publicId":"2838711","version":"1","preferredName":"Primary Effusion Lymphoma","longName":"2838711","preferredDefinition":"An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses.  It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV].  It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients.  The most common sites of involvement are the pleural, pericardial, and peritoneal cavities.  The prognosis is extremely unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Effusion Lymphoma","conceptCode":"C6915","definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A7EC44-0A6F-AA83-E040-BB89AD437747","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C36B-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10003910","valueDescription":"Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"3251329","version":"1","preferredName":"Small Lymphocytic Lymphoma","longName":"3251329","preferredDefinition":"An indolent non-Hodgkin's lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process involves predominantly the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Lymphocytic Lymphoma","conceptCode":"C7540","definition":"A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9BA2-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C380-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10020631","valueDescription":"Monoclonal Gammopathy of Undetermined Significance","ValueMeaning":{"publicId":"2838621","version":"1","preferredName":"Monoclonal Gammopathy of Undetermined Significance","longName":"2838621","preferredDefinition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy of Undetermined Significance","conceptCode":"C3996","definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B0A2-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C394-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10028566","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C3A8-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10035484","valueDescription":"Solitary Plasmacytoma","ValueMeaning":{"publicId":"2951236","version":"1","preferredName":"Solitary Plasmacytoma","longName":"2951236","preferredDefinition":"A single focus of clonal (malignant) plasma cells either in the bone or in another anatomic site without peripheral blood involvement. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solitary Plasmacytoma","conceptCode":"C6932","definition":"A localized malignant neoplasm that arises in the bony skeleton or soft tissue. It is composed of clonal (malignant) plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75819AE4-A79A-9D30-E040-BB89AD430B21","latestVersionIndicator":"Yes","beginDate":"2009-10-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C3BC-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10006597","valueDescription":"Burkitt Leukemia","ValueMeaning":{"publicId":"4722744","version":"1","preferredName":"Burkitt Leukemia","longName":"4722744","preferredDefinition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Leukemia","conceptCode":"C7400","definition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C458-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C471-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10028500","valueDescription":"Mycosis Fungoides","ValueMeaning":{"publicId":"4264966","version":"1","preferredName":"Mycosis Fungoides","longName":"4264966","preferredDefinition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3BBF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C485-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10011677","valueDescription":"Sezary Syndrome","ValueMeaning":{"publicId":"2560040","version":"1","preferredName":"Sezary Syndrome","longName":"2560040","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B795-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C49A-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10012820","valueDescription":"Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"3431650","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","longName":"3431650v1.00","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma._Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCE38D3C-F243-5CA3-E040-BB89AD4307F8","latestVersionIndicator":"Yes","beginDate":"2012-04-04","endDate":null,"createdBy":"LEUNGE","dateCreated":"2012-04-04","modifiedBy":"SOKKERL","dateModified":"2023-11-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C4A4-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10015822","valueDescription":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","ValueMeaning":{"publicId":"4722745","version":"1","preferredName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","longName":"4722745","preferredDefinition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C3898","definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C4AE-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C4C7-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065855","valueDescription":"Nasal Type Extranodal NK/T-Cell Lymphoma","ValueMeaning":{"publicId":"2593089","version":"1","preferredName":"Nasal Type Extranodal NK/T-Cell Lymphoma","longName":"2593089","preferredDefinition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma.  It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells.  The nasal cavity is the commonest site of involvement.  Patients often present with midfacial destructive lesions (lethal midline granuloma).  The disease may disseminate rapidly to various anatomic sites including gastrointestinal tract, skin, testis, and cervical lymph nodes.  It is also known as angiocentric T-cell lymphoma.  The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma.  However, the latter term may also apply to lymphomatoid granulomatosis which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Type Extranodal NK/T-Cell Lymphoma","conceptCode":"C4684","definition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286BA529-8F3E-7325-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C4DB-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10016896","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C4EF-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10047803","valueDescription":"Lymphoplasmacytic Lymphoma","ValueMeaning":{"publicId":"2629954","version":"1","preferredName":"Lymphoplasmacytic Lymphoma","longName":"2629954","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E665ACD-9834-52CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-18","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-04-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Added NCIt concept.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C503-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10026799","valueDescription":"Mantle Cell Lymphoma","ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C517-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10036712","valueDescription":"Mediastinal (Thymic) Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838609","version":"1","preferredName":"Mediastinal (Thymic) Large B-Cell Lymphoma","longName":"2838609","preferredDefinition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Mediastinal Large B-Cell Lymphoma","conceptCode":"C9280","definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AEF5-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C52B-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029462","valueDescription":"Nodal Marginal Zone Lymphoma","ValueMeaning":{"publicId":"4722746","version":"1","preferredName":"Nodal Marginal Zone Lymphoma","longName":"4722746","preferredDefinition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  This is a rare entity, and most patients present with localized or generalized lymphadenopathy.  The clinical course is indolent.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Marginal Zone Lymphoma","conceptCode":"C8863","definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C535-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C54E-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10063908","valueDescription":"Aggressive Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"4722748","version":"1","preferredName":"Aggressive Non-Hodgkin Lymphoma","longName":"4722748","preferredDefinition":"A non-Hodgkin lymphoma with an aggressive clinical course.  Representative examples include Burkitt lymphoma, mantle cell lymphoma, and angioimmunoblastic T-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive Non-Hodgkin Lymphoma","conceptCode":"C9244","definition":"A non-Hodgkin lymphoma with an aggressive clinical course.  Representative examples include Burkitt lymphoma, mantle cell lymphoma, and angioimmunoblastic T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C55B-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C574-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10065856","valueDescription":"Indolent Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"4722750","version":"1","preferredName":"Indolent Non-Hodgkin Lymphoma","longName":"4722750","preferredDefinition":"A non-Hodgkin lymphoma with an indolent clinical course. Representative examples include grade 1 and grade 2 follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indolent Non-Hodgkin Lymphoma","conceptCode":"C8504","definition":"A non-Hodgkin lymphoma with an indolent clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C581-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SOKKERL","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C59A-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"},{"value":"10029593","valueDescription":"Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"2573076","version":"1","preferredName":"Non-Hodgkin Lymphoma","longName":"2573076","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA81-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F8AB028-C5AE-4E21-E050-BB89AD43094A","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"ONEDATA","dateModified":"2015-02-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3121582","version":"1","preferredName":"MedDRA Code","preferredDefinition":"An international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The MedDRA Maintenance and Support Services Organization holds a contract with the International Federation of Pharmaceutical Manufacturers Associations to maintain and support the implementation of the terminology.:A system of numbered categories for representation of data.","longName":"C43820:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MedDRA","conceptCode":"C43820","definition":"An international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The MedDRA Maintenance and Support Services Organization holds a contract with the International Federation of Pharmaceutical Manufacturers Associations to maintain and support the implementation of the terminology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B5D9360-9AE7-B147-E040-BB89AD4340CC","latestVersionIndicator":"Yes","beginDate":"2010-07-14","endDate":null,"createdBy":"BLKLDR","dateCreated":"2010-07-14","modifiedBy":"ONEDATA","dateModified":"2010-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MedDRA:Medical Dictionary for Regulatory Affairs","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F78C75D-7C3E-2AC1-E050-BB89AD437AC5","latestVersionIndicator":"Yes","beginDate":"2015-02-19","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-19","modifiedBy":"KUMMEROA","dateModified":"2023-08-29","changeDescription":null,"administrativeNotes":"2023.8.29 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]},{"publicId":"3533741","version":"1","longName":"NCORP (NCI Community Oncology Research Program","context":"NCIP","ClassificationSchemeItems":[{"publicId":"5023691","version":"1","longName":"Clinical Trial Screening Tool","context":"NCIP"}]}],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"CTEP_SDC_MED_V10_CD","type":"USED_BY","context":"DCP"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Disease code:","type":"Preferred Question Text","description":"Disease code:","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Specific Cancer Diagnosis","url":null,"context":"Theradex"},{"name":"ALT - 1","type":"Alternate Question Text","description":"Simplified Disease Code","url":null,"context":"ECOG-ACRIN"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Simplified Disease Classification (SDC) v10 disease:","url":null,"context":"COG"},{"name":"NCORP Question Text","type":"Alternate Question Text","description":"Disease Code","url":null,"context":"DCP"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDBD6FE-B42C-A4AB-E050-BB89AD43240A","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-02-24","modifiedBy":"SOKKERL","dateModified":"2023-02-22","changeDescription":"9149_Theradex_02.24.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}